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ABSTRACT 
Streptococcus pneumoniae is one of the major contributors to mortality and morbidity 
around the world. It causes a wide variety of diseases ranging from uncomplicated 
respiratory infections to life-threatening invasive infections such as meningitis and 
septicemia. In recent years, the effectiveness of antibiotic therapy has been hampered 
by the increasing rates of resistant pneumococci. As antibiotic resistance increases, 
there is a growing need for interventions that minimize opportunities for development 
and spread of resistant pneumococci. The aim of this thesis was to learn more about 
emergence and spread of antibiotic resistant pneumococci using both theoretical and 
empirical methods.  
Since the increasing prevalence of resistant pneumococci is mainly due to the 
spread of strains belonging to few clones, interventions for controlling pneumococcal 
transmission in the community were studied. Model predictions suggested that 
interventions for efficiently control organism transmission should include reduction of 
group sizes in the day-care centers. Simulations also indicated that it appears extremely 
difficult to reduce the rates of penicillin non-susceptible pneumococci by simply 
decreasing the penicillin consumption assumed that reduced penicillin susceptibility 
does not imply a fitness cost for the organism. Managing the penicillin resistance rates 
in pneumococci then probably requires a more restrictive use of penicillin together with 
other control measures such as vaccine programs. Although clonal spread is the 
primary mechanism for the rapid emergence of resistance in pneumococci, natural 
competence for genetic transformation also seems to be involved. Further molecular 
understanding of competence regulation is important to be able to prevent horizontal 
spread of resistance genes. Studying the competence regulation by theoretical means 
led to the conclusion that down-regulation of competence is probably caused by a 
repressor acting on the comCDE operon at the level of transcription.  
Despite the globally emerging frequency of resistant pneumococci, we conclude 
in a prospective study that antimicrobial resistance in invasive pneumococci in south-
west Sweden remains limited. Any correlations between resistance pattern and clinical 
parameters could not be revealed. However, the serotype distribution was observed to 
differ between strains with reduced susceptibility and fully susceptible strains as 
isolates with decreased susceptibility more frequently belonged to the serotypes 
included in the 7-valent vaccine. 
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1 INTRODUCTION 
1.1 GENERAL MICROBIOLOGY OF STREPTOCOCCUS PNEUMONIAE 
The pneumococcus (Streptococcus pneumoniae or diplococcus) was first isolated 
independently by Louis Pasteur and George Miller Sternberg in 1880. Ever since that 
time, research on this organism has resulted in advancements in our understanding of 
the human response to infectious diseases, natural transformation as a mean of genetic 
exchange, bacterial resistance to antibiotics, as well as vaccine-related 
immunoprophylaxis. In past decades, research on pneumococci has even been 
intensified due to the pneumococcal acquirement of multiple antibiotic resistances, and 
to the development of novel vaccines to counter this problem. Nevertheless, 
pneumococcal diseases remain a leading cause of morbidity and mortality around the 
world, and still there is much to be discovered about the biology of this organism.  
 
1.1.1 Pneumococcal physiology and structure 
S. pneumoniae is a Gram-positive, facultative anaerobe that grows as single cells, 
diplococci or in short chains. The organism is an oval or spherical coccus of 0.5-1.25 
µm in diameter. The pneumococci are α-hemolytic as signified by their formation of 
greenish haloes on blood agar plates. The α-hemolysis, also called partial or incomplete 
hemolysis, is caused by the hydrogen peroxide produced by the bacteria. The hydrogen 
peroxide oxidizes hemoglobin to green methemglobin. The pneumococcal genome 
corresponds to a circular chromosome containing about two million base pairs 
depending on the strain. Around 2,000 genes are encoded by the pneumococcal 
chromosome.  
The pneumococci are surrounded by a thick polysaccharide capsule which 
covers the cell wall. The capsular polysaccharides (CPS) represent a diverse group of 
polymers that play an important role in the virulence of the organism. The 
polysaccharides differ in both their sugar compositions and linkages. Despite this 
diversity, all capsular types perform the same primary function of protecting against 
phagocytic clearance by blocking the deposition and function of opsonins directed 
against cell surface antigens (Abeyta et al. 2003; Hostetter 1986; Szu et al. 1983). 
Thus, non-encapsulated strains have less protection and thereby also greatly reduced 
virulence (Griffith 1928). The antigenicity of the capsule forms the basis for the 
classification of different capsular serotypes. Hitherto, 48 different serogroups have 
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been described, which are further subdivided into a total of 91 serotypes (Park et al. 
2007). The serotypes are distinguished by the ability of the immune system in rabbits to 
recognize chemical differences in the CPS and to respond with specific antibodies 
against antigens of each different type. The system of nomenclature, generally used for 
the pneumococcal serotypes, is referred to as the Danish system and is based on cross-
reactions between different serotypes (Kamerling 2000). Serologically cross-reactive 
serotypes are assigned to a common serogroup with individual serotypes within each 
group distinguished by a trailing letter. The number assignment refers to the serogroup, 
e.g., serogroup 7, which is subdivided into the serotypes 7A, 7B, etc. The host’s 
protective antibodies are directed against the polysaccharide capsule, and the immune 
response is therefore type/group specific with only slight or no cross-reactivity between 
antibodies of different specificity. The role of the pneumococcal polysaccharide 
capsule as virulence factor is further discussed in section 1.5.1. 
 
1.1.2 Competence for natural transformation 
Transformation, which alters the genetic makeup of an individual, was first discovered 
in S. pneumoniae in 1928 by Frederick Griffith. At that time, numerous serologic types 
had been recognized in pneumococci. In Griffith’s laboratory, the research was focused 
on the variation in capsule involved in the serologic differences. He reported that heat-
killed encapsulated pneumococci could transfer the ability to produce a capsule and to 
infect mice when injected together with live, unencapsulated (non-pathogenic) 
pneumococci (Griffith 1928).  
Competence for natural genetic transformation of the type found in 
pneumococci has been reported in about 70 different species of bacteria (Johnsborg et 
al. 2007), for example Haemophilus influenza, Bacillus subtilis, Neisseria meningitidis, 
and Neisseria gonorrhoeae. Natural transformation requires a set of genes evolved for 
the purpose, in contrast to artificial transformation, which is accomplished by shocking 
cells either electrically or by ionic strength and temperature shifts. Such treatments can 
introduce very small amounts of DNA into any type of cell. The genetic material 
introduced by natural transformation is a million fold greater; S. pneumoniae can take 
up as much as 10% of its cellular DNA content (Hotchkiss 1954).  
The regulation of competence differs between bacterial species. In N. 
gonorrhoeae the competence is a constitutive feature, whereas in H. influenzae it is 
induced by starvation (Solomon et al. 1996). In both S. pneumoniae and B. subtilis the 
development of competence is regulated by cell-cell signaling. More precisely, the 
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initiation of competence in pneumococci is regulated by a peptide-controlled quorum 
sensing system called ComABCDE pathway (Figure 1).  
 
 
FIGURE 1  Model of the quorum sensing regulated competence pathway in S. pneumoniae. The signal peptide CSP 
accumulates extracellularly and binds to its receptor, ComD. Binding of CSP elicits a conformational change in ComD 
leading  to autophosphorylation. ComD donors  the phosphate group  to  the  response  regulator ComE which  then 
increases  its  efficiency  as  transcription  factor  significantly.  The alternative  sigma  factor ComX  is  the unique  link 
between quorum sensing and competence development. 
 
The quorum sensing signal is a heptadecapeptide called competence-stimulating 
peptide (CSP), which is encoded by the 3´ moiety of comC (Havarstein et al. 1995). 
The signal peptide is exported by an ABC-transporter, ComAB, which recognizes and 
cleaves the amino-terminus of CSP (Hui et al. 1995). CSP then accumulates 
extracellularly and is sensed by a membrane-bound histidine kinase, ComD, which 
autophosphorylates upon binding CSP. Thereafter, ComD transfers the phosphate 
group to its response regulator, ComE, which functions as a transcriptional activator 
(Ween et al. 1999). Phosphorylation of ComE enhances the affinity for its binding site, 
a conserved direct-repeat motif in the promoter regions of the target genes, leading to 
an increased expression of about 20 early competence genes. Binding sites for ComE 
have been identified upstream of both comAB and comCDE operons (Ween et al. 
1999), and for comX, encoding an alternative sigma factor that has been reported as a 
unique link between quorum sensing and competence development (Luo et al. 2003a; 
Luo et al. 2003b). The expression of late com genes, which encodes proteins involved 
in binding, uptake, processing, and recombination of exogenous DNA, is dependent on 
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ComX which acts by replacing SigA in RNA polymerase (Campbell et al. 1998; Martin 
et al. 1995; Pestova et al. 1998; Peterson et al. 2004). 
Pneumococcal cells are not always competent to take up DNA. In batch 
cultures, competence is induced when CSP reaches an external concentration of 1-10 
ng ml-1 (Havarstein et al. 1995) corresponding to a cell density between 105 and 5 x 108 
cell ml-1 (Chen et al. 1987). Different factors of environment and metabolism such as 
temperature, pH (Chen et al., 1987), cations (Fox et al. 1957), and oxygen 
concentration (Echenique et al. 2000) explain the wide range in cell density at which 
competence can be initiated in a batch culture. The majority of non-competent cells in 
an exponential phase are affected by CSP-induced competence (Havarstein et al. 1995). 
In experimental studies, waves of competence have been observed before the culture 
reaches the stationary phase. However, in the second wave around 12% of the cells 
become competent and any additional waves only involve a minority of the cells (Chen 
et al. 1987; Morrison 1997). Studies on the laboratory strain Rx have demonstrated that 
competence appears as a sharp peak of around 30 min in duration. To date, the 
mechanisms responsible for the shut-off of competence shortly after its induction is not 
clarified and further research is required. However, we examined theoretically the 
competence system regarding plausible mechanisms involved in the competence shut 
off (paper III). Model results suggested that down-regulation of competence probably 
is caused by a hypothetical repressor acting on the comCDE operon at level of 
transcription.  
For transformation to occur under natural conditions, DNA must be released 
from donor cells as well as being taken up by recipient cells. Probably, the transforming 
DNA originates from lysed non-competent pneumococcal cells where lysis was 
triggered by competent cells (Guiral et al. 2005). During the competence development, 
pneumococci express a putative murein hydrolase, CbpD, which mediates lysis of non-
competent target cells in the surrounding environment (Eldholm et al. 2009). The 
competent attacker cells, which protect themselves against their own lysins by an 
immunity protein encoded by the comM gene, are able to take up the DNA released 
from the lysed cells (Håvarstein et al. 2006). The exact mode of actions of CbpD and 
ComM has not been determined yet. The major pneumococcal autolysin, LytA, appears 
to be constitutively expressed in pneumococci, but during competence development its 
expression is enhanced (Peterson et al. 2004). Another cell wall hydrolase, LytC, has 
also been reported to contribute to the lysis mechanism although it is not a part of the 
competence regulon (Eldholm et al. 2010).  
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The possible benefits of natural competence in bacteria have been discussed, 
but competence is probably advantageous because of its role in horizontal gene transfer 
and it might also aid in the repair of damaged chromosomes (Solomon et al. 1996). 
Since natural transformation in S. pneumoniae mediates intraspecies as well as 
interspecies gene transfer, it gives the pneumococcus access to a large gene pool, which 
it shares with other pneumococcal strains and closely related streptococci (Hiller et al. 
2007). Under certain types of stress such as antibiotics, genes present in the common 
gene pool that give a selective advantage will spread rapidly among these bacteria. In 
pneumococci, natural transformation is most likely to be responsible for serotype-
switching, and has also influenced the evolution of virulence factors (Coffey et al. 
1991; Coffey et al. 1998; Hollingshead et al. 2000; Kelly et al. 1994; Ween et al. 1999) 
and the rapid emergence of antibiotic resistance (Coffey et al. 1991; Dowson et al. 
1989; Hakenbeck et al. 1998).  
 
1.2 PNEUMOCOCCAL CARRIAGE AND TRANSMISSION 
The human nasopharynx is the primary reservoir for S. pneumoniae and the main 
source of person-to-person transmission. Pneumococcal carriage is mostly transient and 
asymptomatic, but constitutes as well a prerequisite to pneumococcal disease. In 
contrast to diseases that do not have a carrier state, asymptomatic carriers of 
pneumococci contribute more to pneumococcal transmission than infected individuals.  
Transmission occurs from person-to-person via droplets meaning that close contact is 
required for transmission to occur.  
Because the preconditions for acquiring resistance by transformation and 
conjugative transposons are stringent and de novo resistance for the majority of 
antibiotic classes does not result from a single point mutation, the evolution of novel 
resistant pneumococci from an initially sensitive strain occurs only rarely. However, 
once in existence and under the selective pressure of antibiotics, resistant strains are 
able to spread widely. For most of the major antibiotic classes, resistant pneumococci 
are spread primarily by clonal amplification. Consequently, infections caused by 
resistant pneumococci result mostly from the acquisition of resistant strains from other 
nasopharyngeal carriers in the surrounding.  
Primarily children are colonized by S. pneumoniae, whereas adults seldom are 
carriers. In Sweden, between 15-50% of the children are colonized, depending on age 
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and frequency of contacts with other children (Borres et al. 2000; Söderström 1990). 
Among the adults, around 3% habit pneumococci in nasopharynx (Kalin 1982). In 
developing countries, pneumococcal carriage is even more common; as many as 85% 
of the young children can be colonized (Huebner et al. 1998). Seasonal variations in 
nasopharyngeal carriage have been observed; it is more common to be colonized in the 
winter months compared with summer season (Hendley et al. 2005; Marchisio et al. 
2001).  
The duration of carriage varies depending on the host’s age and on the serotype 
of the colonizing strain (Ekdahl et al. 1997; Hogberg et al. 2007). Typically, the 
carriage duration ranges from one month up to a year. It appears to be an inverse 
relationship between age and duration (Ekdahl et al. 1997; Hogberg et al. 2007). 
Isolates belonging to serotype 19F, 23F, 6B, and 35F have been reported to be carried 
in the nasopharynx for 13-32 weeks, whereas serotype 12F, 3, 15B/C, and 9V reside for 
five to eight weeks (Sleeman et al. 2006). Duration of carriage for serotype 1, 4, 5, and 
9A could not be determined since the sampling intervals were longer than two weeks. 
These serotypes obviously inhabit the nasopharynx for a shorter time (Sleeman et al. 
2006). In concurrence, other studies have reported that serotype 1 and 4 are rare or 
absent among carriers, whereas serotype 6A, 6B, 19F, and 23F are more commonly 
found (Brueggemann et al. 2003; Henriques Normark et al. 2003; Sandgren et al. 
2004). 
Nasopharyngeal carriage varies by geographic region. Perhaps the variation in 
the prevalence of nasopharyngeal carriage is due to genetic differences in the host that 
influence the likelihood of nasopharyngeal colonization and also to socioeconomic 
conditions such as crowding, hygiene, family size, and day-care contact (Schrag et al. 
2000).  
 
1.3 CLINICAL DISEASES 
The spectrum of diseases caused by S. pneumoniae is wide, from mild, mucosal 
infections such as sinusitis and otitis media to more severe, invasive diseases as 
septicemia and meningitis. The factors involved in the transition from carriage to 
disease remain inadequately understood. Existing data indicate that the risk for disease 
progression is greatest soon after exposure and acquisition of pneumococci in 
nasopharynx (Gray et al. 1980). The risk for disease progression differs between ages 
and different disease manifestations. Currently, pneumococcus is the most common 
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etiological agent causing otitis, sinusitis, and community-acquired pneumonia (CAP) 
(Iwarson-Norrby 2007). The majority of pneumococcal diseases occur when organisms 
are spread from an area that is colonized into a space that is normally not colonized, 
such as Eustachian tube, paranasal sinus, bronchiole, alveolus, or fallopian tube. The 
most common pneumococcal diseases are described more in detail in this section. In 
addition to these clinical manifestations, pneumococci may also cause other infections, 
although more rarely, such as conjunctivitis, septic arthritis, and endocarditis, etc.  
 
1.3.1 Sinusitis 
Sinusitis is a group of disorders where the sinuses and nasal passages are inflamed. The 
most common direct cause of acute sinusitis is bacteria. In children and elderly, acute 
bacterial sinusitis is an uncommon disease; around 90% of the cases are observed in the 
ages between 15-65 years (Iwarson-Norrby 2007). About half of the sinusitis cases are 
caused by pneumococci; other important pathogens include H. influenzae and 
Moraxella catarrhalis. The symptoms for acute sinusitis may vary but is often 
manifested by purulent nasal drainage, nasal obstruction, fever, cough, headache, and 
facial pain-pressure. The location of pain depends on which sinus is affected.  
 
1.3.2 Otitis media 
Acute otitis media (AOM) is an infection in the middle ear, often caused by bacteria. It 
is one of the most frequent diagnoses in young children in Sweden; at the age of four 
years, around half of the children have experienced at least one otitis and nearly a 
quarter have had two or more episodes (Iwarson-Norrby 2007). The frequency declines 
with increasing age and is rather uncommon after the age of six years. The bacteria 
most often involved in otitis belong to the commensal flora of the naso- and 
oropharynx. In Sweden, the dominating etiologic agent for otitis is S. pneumoniae, 
causing between 30-50% of the cases, followed by H. influenzae, M. catarrhalis, and 
sometimes Streptococcus pyogenes (Iwarson-Norrby 2007).  
Otitis media is defined as the presence of effusion behind the tympanic 
membrane within the middle ears, whereas AOM is an infection characterized by rapid 
onset of symptoms of middle ear inflammation and effusion. Common symptoms are 
fever, otalgia, headache, hearing impairment, nausea, balance problems, purulent 
effusion in the middle ear, and inflammation or bulging of the tympanic membrane 
(Lieberthal 2006; Ramakrishnan et al. 2007). Otitis media has a very low mortality, 
although there are a numbers of more severe complications such as meningitis, acute 
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mastoiditis, reduction in hearing or total hearing loss, and chronic otitis media, which 
may affect children. Persistent morbidity due to otitis media is more common in 
developing countries due to lack of antibiotics (Klein 2000). Even a successful 
treatment of AOM, i.e., eradication of isolates from the middle ear fluid, may result in 
recurrent AOM caused by nasopharyngeal carriage since antibiotic does not always 
clear the nasopharynx from pneumococci (Libson et al. 2005).   
 
1.3.3 Pneumonia 
Pneumonia is defined as an inflammation, often infection-triggered, of one or both 
lungs with consolidation. The most common etiological agent of CAP is the 
pneumococcus, which is believed to be responsible for 25-45% of the cases which in 
turn corresponds to 60-70% of all bacterial CAP (Iwarson-Norrby 2007; Lutfiyya et al. 
2006). Examples of other common bacterial causes of CAP include Mycoplasma 
pneumoniae, H. influenzae, Legionella spp., and Chlamydia pneumoniae (Iwarson-
Norrby 2007). Pneumococcal pneumonia can affect all age groups. The clinical signs of 
pneumonia vary depending on age and causative agent as well as other factors. 
However, the most frequent symptoms of pneumonia among elderly children and adults 
are cough with sputum production, fatigue, fever, chills, sweats, and shortness of breath 
(Buttery et al. 2002). In very young children and the elderly, the symptoms are often 
non-specific which make it difficult to diagnose the disease (Andrews et al. 2003).  
In contrast to CAP, nosocomial pneumonia is aquired at hospitals or long-term 
care facilities. It can be caused by various agents, for example Staphylococcus aureus, 
Pseudomonas aeruginosa and Gram-negative enterobacteria, which of the relative 
frequencies vary with geographic locations, seasons, age of the patient, etc (Iwarson-
Norrby 2007). The pneumococcus may also cause nosocomial pneumonia, especially 
among elderly people in long-term care facilities (Iwarson-Norrby 2007).  
 
1.3.4 Septicemia 
Septicemia, also referred to as sepsis, is a serious medical condition characterized by a 
whole-body inflammatory state, termed a systemic inflammatory response syndrome, 
and the presence of an infection. Systemic inflammatory response syndrome can be 
indicated by symptoms like fever >38oC or < 36oC, respiratory rate >20 breaths/min, 
pulse more than 90 beats/min, and white blood cell count <4,000 cells/mm3 or >12,000 
cells/mm3. For a sepsis characterization, at least two of these symptoms most be 
presented (Nguyen et al. 2006). There are different levels of sepsis and a classification 
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system has been established, which includes sepsis, severe sepsis, and septic shock. The 
symptoms of bacterial sepsis are mainly due to an immunologic hyper reaction 
occurring when bacteria enter the blood stream and thereby activate macrophages and 
other cells to release cytokines, such as interleukin-1 and tumor necrosis factor. In 
massive infections, the production of cytokines reaches uncontrollable and 
detrimentally high levels systematically. The high levels of these proinflammatory 
proteins induce the systemic effects of sepsis. This response triggers the complement 
system and coagulation pathways which then cause damage to the vasculature as well 
as to the organs. Typical clinical symptoms consist of high fever or hypothermia, 
hypotension, shivering, tachycardia, skin rashes, and tachypnoea. In the case of septic 
shock, the symptoms also include increased vasopermeability and vasodilation, which 
may progress to organ failure and death.  
The dominating infectious agent for bacterial sepsis depends on the age. During 
the first week after birth, infections with Escherichia coli, group B streptococci and 
Listeria monocytes are dominating, whereas during the childhood and up to 20 years, 
pneumococci, N. meningitidis, and S. aureus are more common (Iwarson-Norrby 
2007). In adult patients, septic infections are most often caused by Gram-negative 
enterobacteria (Iwarson-Norrby 2007). The pneumococcus is estimated to be the 
causative agent in around 10% of the cases of severe sepsis and septic shock (Iwarson-
Norrby 2007).  
 
1.3.5 Meningitis 
Meningitis is an inflammation of the meninges surrounding the brain and spinal cord. It 
can be caused by viruses, bacteria or other microorganisms. Which types of bacteria 
that commonly cause bacterial meningitis vary between age groups. Pneumococcus is a 
common etiological agent for meningitis occurring in very young children between one 
month to one year of age and in adults older than 40 years (Iwarson-Norrby 2007). 
Examples of other causative agents include N. meningitidis, E. coli, group B 
streptococci, L. monocytes, and H. influenzae (van de Beek et al. 2004). Bacterial 
meningitis often arises secondarily to an infection focus outside the central nervous 
system; pneumococcal meningitis can for example be secondary to AOM (so called 
otogenic meningitis) or to respiratory tract infection (Iwarson-Norrby 2007). Typically, 
symptoms come quickly and may include high fever, severe headache, stiff neck, 
confusion, nausea, photophobia, and general signs of illness. The mortality rate for 
pneumococcal meningitis is high, ranging from 15% to 60% (Burman et al. 1985; Hoen 
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et al. 1993; Kornelisse et al. 1995; Kragsbjerg et al. 1994; Traore et al. 2009). Besides, 
the survivors of pneumococcal meningitis are more likely to suffer from sequele, such 
as hearing loss, neurological complications or neurophysiological impairment, than 
survivors of other forms of meningitis (Jit 2010) 
 
1.4 PATHOGENESIS  
The pathogenesis of pneumococcal infection is a complex interplay between 
pneumococcal virulence factors and the host immune response. Even if S. pneumoniae 
possess a collection of characteristics that allow it to colonize a variety of niches, the 
disease manifestations are caused mainly by the host response rather than the 
production of toxic factors. Principally, all pneumococcal infections begin with 
colonization of the nasopharynx. Several interacting factors determine whether the 
colonizing organisms go on to establish infection of the lower respiratory tract. 
Following the colonization of nasopharynx, the bacteria may spread to the lungs, the 
paranasal sinuses, or middle ear (Figure 2). It can also be transported in the blood to the 
brain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2  Pathogenic routes for pneumococcal infection. A prerequisite for pneumococcal disease is colonization 
of nasopharynx. From here, the bacteria can spread and cause mucosal infections such as otitis media and sinusitis, 
but also more serious conditions like pneumonia, septicemia, and meningitis can arise. 
 
Initially, the colonization of nasopharynx is mediated by the attachment of the bacteria 
to epithelial cells by means of surface protein adhesins. Pneumococcal factors that have 
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been indicated to promote binding to epithelial cells include choline, pneumococcal 
neuraminidase, and CbpA (Cundell et al. 1995a; Rosenow et al. 1997; Tong et al. 
2000). On the host epithelial cells, the target molecules are usually sugars as 
disaccharides and sialic acid, but the platelet-activating factor receptor can be used as 
well (Cundell et al. 1995a). If the organisms are enveloped in mucus and removed from 
the airways by the action of ciliated epithelial cells, subsequent migration of the 
pneumococci to the lower respiratory tract can be prevented. However, this mucus 
envelopment is counteracted by the bacteria by their production of immunoglobulin 
(Ig) A protease and pneumolysin (Kornfeld et al. 1981). Human secretory IgA acts by 
trapping bacteria in mucin by binding itself to the bacteria at the antigen-binding site 
and to mucin. This interaction can be interfered by bacterial IgA proteases which are 
capable of cleaving secretory IgA. Pneumolysin also plays an important role in evading 
the host defense by binding to cholesterol in the host cell membrane and causing pores, 
thereby destroying ciliated epithelial cells and phagocytic cells.  
Pneumococcal colonization has been reported to correlate with observed 
differences in colony phenotypes. This human pathogen seems to undergo spontaneous, 
reversible opacity phase variation with a frequency of 10-3 to 10-6 resulting in opaque 
and transparent colonies (Weiser et al. 1994), where the transparent phenotype 
produces less CPS and has an enhanced ability to reside on mucosal surfaces when 
tested in animal models (Tong et al. 2001). By contrast, it appears that the opaque 
variant is more virulent in systemic infections probably because the higher levels of 
CPS production make them more resistant to complement-mediated 
opsonophagocytotic elimination (Kim et al. 1998). 
Presumably, pneumococci spread to the lungs by aspiration. It has been 
indicated that the attachment of pneumococci occurs to bronchial epithelial cells 
(Adamou et al. 1998) or to components of the basement membrane including laminin, 
collagen and fibronectin (Kostrzynska et al. 1992; van der Flier et al. 1995). An 
impaired ciliary beating frequency due to damage caused by the release of pneumolysin 
or by smoking, promotes the binding of pneumococci. Pneumolysin inhibits the normal 
beating of cilia by destroying epithelial and endothelial cells and thereby making it 
easier for the organisms to enter the blood stream (Steinfort et al. 1989; Zysk et al. 
2001). Following influenza virus infection, adherence of pneumococci to tracheal 
epithelial cells is enhanced by viral neuraminidase (Plotkowski et al. 1986). This 
enzyme cleaves sialic acid from glycosphingolipids in human lung tissue and thereby 
exposing other structures that function as receptors for adhering pneumococci (Krivan 
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et al. 1988). Viral infections may also facilitate the binding of pneumococci by 
affecting epithelial cells to upregulate the platelet-activating factor receptor and by 
damaging bronchial epithelium (McCullers et al. 2010; Obaro et al. 1996). 
Inside the alveoli, pneumococci bind to type II pneumocytes and can spread 
rapidly into the blood by crossing the vascular endothelium (Tuomanen et al. 1995). 
Once the bacteria have reached blood stream, several factors are required. The most 
essential is the antiphagocytotic capsule, but pneumolysin, pneumococcal surface 
protein A, and CbpA also play an important role by the interfering with complement 
activation (Cheng et al. 2000; Mitchell et al. 1991; Tu et al. 1999). During 
pneumococcal pneumonia, three different stages of lesions were distinguished: (1) 
engorgement, (2) red hepatisation, and (3) gray hepatisation. The first stage, 
engorgement, is associated with the accumulation of a serous exudate in the alveoli. 
Thereafter, a leakage of erythrocytes into the alveoli occurs. During the last stage, 
bacterial multiplication peaks and fibrin is formed through the procoagulant activity 
induced by pneumococci. Furthermore, neutrophils recruited to the infection site begin 
to control pneumococcal multiplication (Tuomanen et al. 1995). However, clearance of 
pneumococci by opsonophagocytosis depends further on complement and is facilitated 
by anti-capsular antibodies (AlonsoDeVelasco et al. 1995). The tissue destruction often 
observed in pneumococcal pneumonia is primarily due to the host´s inflammation 
response, thereof the remarkable feature of pneumococcal pneumonia that the lungs of 
surviving patients almost invariably return to normal, irrespective of the severity of the 
systemic or pulmonary condition when the disease was at its peak (Catterall 1999).  
 
1.5 VIRULENCE FACTORS 
Over the years, several pneumococcal virulence factors have been identified, some 
more investigated than other. In this section, some of the major and most well-known 
virulence factors are to be described (Figure 3).  
 
1.5.1 Polysaccharide capsule 
The capsule has been recognized as the principal virulence factor of S. pneumoniae. 
Encapsulated strains have been found to be at least 105 times more virulent than strains 
lacking capsule (Watson et al. 1990). Basically all clinical isolates possess a capsule, 
and non-encapsulated mutants are considered avirulent (Griffith 1928; Watson et al. 
1990). Based on the chemical structure of the capsules more than 90 different capsular 
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types have been described so far (Park et al. 2007). The capsule consists of a mix of 
repeating units of polysaccharides and varies in complexity. The main role of the 
capsule is to protect against phagocytosis by macrophages and neutrophils by inhibiting 
C3b opsonisation of the pneumococcus. The chemical structure and, to a lesser extent, 
the thickness of the capsule seems to be important determinants for the differential 
ability of serotypes to survive in the bloodstream and possibly to cause IPD. Studies 
have also shown that the capsule is essential for colonization (Magee et al. 2001; 
Nelson et al. 2007).  
 
 
 
FIGURE 3  Some of the major pneumococcal virulence factors including polysaccharide capsule, cell wall fragments 
(PG, TA, and LTA), LytA, pneumolysin, pneumococcal surface proteins, choline binding proteins, and neuraminidase. 
Pilus‐like structures are found in some pneumococci.  
 
1.5.2 Cell wall fragments 
The pneumococcal cell is also surrounded by a cell wall, which is a thick multi-layered 
structure built up mainly by peptidoglycan (PG), teichoic acid (TA), and lipoteichoic 
acid (LTA). Studies have shown that pneumococcal cell wall preparations induce 
inflammation similar to what has been observed with whole pneumococci (Fischer et 
al. 1993; Mosser et al. 1970). Otitis media, meningitis, and pneumonia are examples of 
typical pneumococcal diseases that have been demonstrated to be mimicked in animals, 
which have received injection of purified cell wall or its degradation products (Carlsen 
et al. 1992; Tuomanen et al. 1985; Tuomanen et al. 1987). Cell wall fragments activate 
the alternative pathway of complement (Winkelstein et al. 1977; Winkelstein et al. 
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1978). The anaphylatoxins C3a and C5a, which enhance vascular permeability, 
provoke mast cell degranulation, recruit and activate polymorphonuclear leukocytes at 
the site of inflammation, are produced during complement activation (Johnston 1991). 
Several studies have reported that anti-cell wall polysaccharides or anti-
phosphorylcoline antibodies protect animals against pneumococcal challenge (Briles et 
al. 1981; Briles et al. 1992; Briles et al. 1989; Kenny et al. 1994; Nicoletti et al. 1993), 
whereas such a protection was not observed by other (Nielsen et al. 1993; Szu et al. 
1986).  
 
1.5.3 Pneumolysin 
Pneumolysin is an intracellular thiol-activated toxin present in almost all clinical 
isolates that has a variety of toxic effects on different cell types. Previously, 
pneumolysin was thought to not be secreted by pneumococci, only released upon lysis 
of the bacterium under the influence of autolysins. However, in 2001, a secretion 
mechanism for pneumolysin was suggested (Balachandran et al. 2001). This toxin is 
believed to have multiple functions in virulence as it possesses both cytotoxic and pro-
inflammatory properties. At high concentration, pneumolysin binds to cholesterol in 
host cell membranes and may disrupt them by forming transmembrane pores. At lower 
concentrations, it stimulates the production of inflammatory cytokines such as tumor 
necrosis factor-α and interleukin-1β (Houldsworth et al. 1994), decreases the 
bactericidal activity and migration neutrophils (Paton et al. 1983), and activates the 
classical complement pathway by binding to the Fc portion of nonspecific antibodies 
and thereby causing inflammation tissue damage (Mitchell et al. 1991).  
 
1.5.4 Autolysins 
Autolysins, also called bacterial cell wall hydrolases, are enzymes that specifically 
cleave bonds of the cell wall. This cleavage makes the cell unstable and sensitive to 
osmotic pressure that causes lysis and death of the bacteria. The major autolysin in 
pneumococci is LytA, a choline-binding protein located in the cell wall. LytA is 
required for daughter cell separation and pneumococcal lysis in stationary phase as well 
as in the presence of penicillin. In 1989, it was shown that LytA-negative mutants were 
less virulent than wild-type pneumococci (Berry et al. 1989). However, the effect of 
LytA seems to be mediated by the release of pneumolysin from the pneumococcal 
cytoplasm during infection because immunization with autolysin does not protect 
against challenge with a pneumolysin-negative mutant (Lock et al. 1992). Analyses of 
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expression data have shown that the lytA gene is over-expressed during competence 
development (Peterson et al. 2000). The reason for this finding is still unclear as it is 
established that LytA is not required for transformation (Sánchez-Puelles et al. 1986). 
Two other autolysins, LytB and LytC, are also described but their functions are less 
understood.  
 
1.5.5 Phase variation 
Weiser et al. showed in 1994 that S. pneumoniae is able to make two different colony 
types, a transparent colony type and an opaque colony type when grown on agar plates 
(Weiser et al. 1994). The impact of this reversible phase variation has been further 
examined since then. It has been suggested that the pneumococcus phase varies 
between a virulent opaque form expressing more CPS and less TA, and an avirulent 
transparent form with less CPS and more TA (Kim et al. 1998). Probably, the different 
appearances in colonies reflect differences in surface molecules that may mediate 
adherence. Strains with the transparent colony type adhere much more tightly to human 
epithelial cells in vitro and are also more potent colonizers in animal models (Cundell 
et al. 1995b; Weiser et al. 1994). More precisely, the enhanced colonization of the 
nasopharynx in vivo by transparent phase variants involves a greater ability to adhere to 
GlcNAc (N-acetylglucosamine) which is a major receptor during colonization (Cundell 
et al. 1995b). In systemic infections, the virulent opaque variant has been found to be 
more resistant against complement-mediated opsonophagocytotic elimination by the 
high-level expression of CPS (Kim et al. 1998). 
 
1.5.6 Pilus-like structures 
Recently, pilus-like structures were recognized in pneumococci (Barocchi et al. 2006). 
These pili were found to be encoded by the rlrA pathogenicity islet and appear to be 
present in some, but not all clinical isolates. A study from 2008, reported that only a 
minority, around 27%, of clinical invasive isolates harbored the pilus islet which 
indicates that it is not an essential virulence factor (Aguiar et al. 2008). However, 
piliated pneumococci have been demonstrated to be more virulent as piliated 
pneumococci have been shown to outcompete non-piliated mutants in a mouse model 
of colonization, pneumonia, and bacteremia (Barocchi et al. 2006).  
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1.6 HOST RESPONSE 
1.6.1 Immune system 
Most symptoms of pneumococcal disease are generated by the host inflammatory 
response. The host immune response is composed of two major subdivisions, the innate 
immunity and the adaptive immunity. The innate immune system provides a rapid, non-
specific first line of defense against invading microbes. It includes immune cells such 
as macrophages, neutrophils, and natural killer cells as well as specialized chemical 
mediators as cytokines, and the complement cascade. It is present from birth and does 
not require pre-exposure to foreign microbial material to react. Innate immunity can 
directly react against a large number of microbes by recognizing highly conserved 
molecular microbe specific motifs such as bacterial PG and LTA. The innate 
recognition is achieved through a limited set of germline-encoded receptors and does 
not possess immunological memory. These highly conserved molecular motifs are also 
called pathogen-associated molecular patterns and are recognized by Toll-like receptors 
(TLRs) and other pattern recognition receptors such as the soluble acute phase protein 
called lipopolysaccharide-binding protein (Weber et al. 2003) and the cytosolic NOD-
like receptors. Many TLRs have been implicated to be involved in the recognition of 
pneumococci. For example, TLR4 has been shown to recognize pneumolysin (Malley 
et al. 2003) whereas TLR2 seems to recognize pneumococcal LTA as well as PG 
(Koedel et al. 2003). Another well-known example of pattern recognition receptors 
involved in the response to the pneumococcus is C-reactive protein (CRP). This soluble 
protein binds phosphorylcholine located in the cell wall and thereby induces 
complement activation and bacterial destruction 
A part of the innate immunity, which plays an important role in clearance of the 
bacteria during a pneumococcal infection, is the complement system. It consists of 
more than 30 serum and membrane proteins which, when activated, form an enzymatic 
cascade of reactions contributing to the elimination of invading microbes. The binding 
and activation of complement proteins to the bacterial surface results in 
opsonophagocytosis and inflammation induction. Opsonophagocytosis appears to be 
the major immune mechanism protecting the host against pneumococcal infection 
(Bruyn et al. 1992). Complement can also destroy some microorganisms, however, not 
the pneumococcus, directly through lysis by the membrane attack complex. Humans 
with deficiencies in the complement pathways have been reported to have an increased 
susceptibility to pneumococcal infections (Picard et al. 2003; Revest et al. 2009; Totan 
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2002). Three different activation pathways of the complement have been identified. 
However, the classical pathway of activation is the dominating one for pneumococci, 
where complement is activated by antigen-antibody complexes or the binding of acute-
phase proteins, for example CRP, to the bacterium (Brown et al. 2002). To a lesser 
degree than the classical pathway, the alternative pathway also appears to contribute to 
innate protection, whereas the role for the lectin pathway seems negligible. The 
deposition and activation of the complement component C3 on the surface of the 
microbe is a key step in the enzymatic cascade that will clear the bacteria. In 
accordance with the importance of this component, the pneumococcus has evolved 
mechanisms to resist its affect. A crucial determinant in this resistance is the capsule 
which acts to limit the access to cell bound complement and to reduce the amount of 
complement deposited as well (Abeyta et al. 2003). 
The innate immune system also constitutes the link to the adaptive immune 
system consisting of antigen-specific reactions through T-cells and B-cells. The 
adaptive immunity possesses a memory so that subsequent exposure leads to a stronger 
and faster response. When extracellular pathogens such as pneumococci are engulfed 
and killed by antigen presenting cells, bacterial proteins are digested and presented by 
the major histocompatibility complex II (MHC-II) on the surface of antigen presenting 
cells. These antigen peptide/MHC-II-complexes are then recognized by specific 
lineages of T-cells which become activated upon binding. This leads to clonal 
expansion of immune cells capable of mediating a specific antibody or cellular immune 
response directed against the invading microorganism.  
So far, the exact mechanisms for the involvement of T-cells in pneumococcal 
infections are not fully understood. However, CD4+ T-cells are important in 
establishing and maximizing the capabilities of the adaptive immune response. These 
cells can not kill infected cells or clear pathogens since they have no phagocytic or 
cytotoxic activity. Instead they possess a managing role in the immune response by 
directing other cells to perform these tasks. Kemp et al. investigated in vivo the levels 
of activated CD4+ T-cells producing type 1 cytokines in the circulation. They found 
that activated T-cells with a type 1 cytokine profile decreased early in the acute phase 
of the pneumococcal infection suggesting that these cells are highly engaged in the in 
vivo immune response to pneumococci (Kemp et al. 2002). The underlying 
mechanisms for this disappearance may be increased apoptosis and/or sequestration in 
the peripheral tissues.  
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Adaptive immunity to extracellular bacteria, such as S. pneumoniae, is largely 
conferred by antibodies. Pneumococci are rapidly cleared from the blood, mainly by 
the liver and to a lesser extent by the spleen, in the presence of anti-capsular antibodies, 
however, complement is required to achieve effective clearance (AlonsoDeVelasco et 
al. 1995). Immunoglobulin responses specific for pneumococcal protein and 
polysaccharide antigens are induced through distinct mechanisms (Mond et al. 1995). 
Capsular polysaccharide antigens elicit antibodies that are isotype restricted to IgM and 
IgG2 and in a lesser extent to IgG1 in humans, and IgM and IgG3 in mice 
(AlonsoDeVelasco et al. 1995). Polysaccharides are unable to recruit cognate CD4+ T-
cell help through T-cell receptor recognition of peptide/MHC-II complexes on the 
surface of antigen presenting cells. Instead, the regularly spaced repeating epitopes 
expressed by polysaccharides induce multivalent membrane immunoglobulin cross-
linking on the B-cell surface leading to only B-cell proliferation. Therefore, capsular 
polysaccharides yield no anamnestic response and are weakly immunogenic in children 
under two years of age. Although polysaccharides fail to associate with MHC-II, their 
co-expression with proteins by an intact microbe could mediate cognate CD4+ T-cell 
help for polysaccharide-specific B-cells. The immune response to T-cell dependent 
antigens critically depends on the interaction between CD40 ligand on the surface of 
activated CD4+ T-cells, and CD40 expressed on the surface of B-cells. This interaction 
stimulates the resting B-cell to secrete antibodies to T-cell-dependent antigens. During 
an in vivo response to intact pneumococci, the blocking of CD40-CD40 ligand 
interactions inhibited induction of immunoglobulin specific for capsular 
polysaccharides (Hwang et al. 2000).  
Hitherto, the impact of innate cytokine release on the subsequent development 
of the adaptive antibody response to an extracellular bacterium is not fully understood. 
There are, however, studies of tumor necrosis factor, a proinflammatory cytokine, 
which strongly suggest a link between cytokines released during the early, innate 
response and the subsequent development of adaptive humoral immunity 
(AlonsoDeVelasco et al. 1995). The quality and strength of the humoral response 
appears to be balanced by the concomitant secretion of a panel of cytokines having 
opposing actions, and which regulate differentially in vivo polysaccharide- and protein-
specific immunoglobulin response to S. pneumoniae (Khan et al. 2002).   
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1.6.2 Immune response to vaccines 
Currently there are two different pneumococcal vaccine formulations, polysaccharide 
vaccine and conjugate vaccine, available on the market. These two vaccine types differ 
in immunogenicity. Polysaccharide vaccines are based on extracted and purified forms 
of the bacterial polysaccharide capsule. The rationale behind these purified 
polysaccharide vaccines is that they would trigger the production of circulating 
antibodies, which then would cover the bacterial capsules with antibodies and/or 
complement, promoting phagocytosis and removal by cells (e.g., macrophages and 
neutrophils) of the innate immune system. However, purified polysaccharides cannot 
be presented via MHC-II for CD4+ T-cells. Instead they activate B-cells in a T-cells 
independent manner by cross-linking antibodies on the B-cell surface, which results in 
the formation of plasma B-cells and antibodies without the help of CD4+ T-cells 
(Griffioen et al. 1992). Consequently, IgM is the predominant isotype generated due to 
little class switching, no affinity maturation, and little development of memory cells. 
Vaccines composed solely of purified polysaccharides are only effective in older 
children and adults for a period of three to five years. They are not effective for infants 
and very young children under two years of age, who have immature immune systems 
(Cowan et al. 1978). Therefore, conjugate vaccines have been developed. These 
protein-polysaccharide vaccines link purified bacterial polysaccharides to purified 
protein carrier, which involve CD4+ T-cells in the polysaccharide antigen response. The 
protein carrier of the conjugate vaccine leads to antigen presentation on antigen 
presenting cells. The interaction between B-cells and CD4+ T-cells permit class 
switching from IgM to IgG and affinity maturation of antibody, which makes plasma 
cells more specific, longer-lasting effectors. Memory cells are also induced to 
participate in a secondary response upon exposure to the pathogen. Several protein 
carriers have been used in conjugate vaccine strategies, for example tetanus toxoid, 
diphtheria toxoid, and a non-toxic variant of diphtheria toxin referred to as CRM197. 
These protein carriers were all selected on the basis of their capacity to activate CD4+ 
T-cells (AlonsoDeVelasco et al. 1995). In pneumococcal vaccines, pneumococcal-
CRM conjugates have been most extensively studied. Each of the included 
polysaccharides is in that case coupled to CRM197. More about pneumococcal vaccines 
and their effects is to be found in section 1.8.6.  
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1.7 EPIDEMIOLOGY 
1.7.1 Incidence 
Pneumococcal disease is endemic all over the world. In 2002, World Health 
Organization (WHO) estimated that approximately 1.6 million deaths occurred around 
the world as a result of pneumococcal disease (2005). Pneumococcal pneumonia alone 
is responsible for more than one million deaths annually, making it one of the leading 
infectious causes of mortality. Around half of the deaths caused by pneumococcal 
diseases occur in young children (<5 years), mainly in developing countries. In the 
developed world, pneumococcal infection is more common as a cause of death among 
the elderly than in young children.  
Mucosal infections are usually less severe but much more common than 
invasive infections (Figure 4). In Sweden, the pneumococcus is estimated to annually 
account for between 30,000 and 70,000 cases of AOM (Läkemedelsrådet 2009), and 
around 80,000 cases of sinusitis (Läkemedelsrådet 2009).  
 
 
FIGURE 4  For  the most  common  diseases  caused  by  pneumococci,  there  is  an  inverse  relationship  between 
disease severity and prevalence. Adapted from Edwards, KM., Pneumococcal Infections: Therapeutic Strategies and 
Pitfalls. In The Pneumococcus. (2004) ASM Press, Washington D.C.  
 
Concerning pneumonia, S. pneumoniae dominates as an etiologic agent of CAP in all 
age groups and is probably responsible for nearly half of the cases (Iwarson-Norrby 
2007). The yearly incidence of CAP for adults is around 1% but increases with age 
(Iwarson-Norrby 2007). For young children below five years of age the corresponding 
incidence is higher, between 3-4%, whereas among children 5-14 years the incidence is 
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1-2% (Iwarson-Norrby 2007). The corresponding figures in rest of Europe and in the 
United States are roughly the same.  
The incidence of IPD seems to vary substantially by age, ethnicity, geographic 
location, socioeconomic status, and immune status (van der Poll et al. 2009). In isolated 
indigenous populations, such as Aboriginal Australians, the Maoris of New Zealand, 
and Alaskan Eskimos, the yearly incidence rates of IPD among children have been 
reported to be as high as 441 cases per 100,000 individuals (Bruce et al. 2008; Voss et 
al. 1994). According to WHO, the annual incidence for pneumococcal bacteremia in 
Western populations is between 15-19 cases per 100,000 individuals, whereas the 
corresponding number for meningitis is 1-2 (WHO 2003). In Sweden, the total annual 
incidence of pneumococcal meningitis is at least 1 per 100,000 individuals, whereas of 
pneumococcal bacteremia it is around 15 per 100,000 (Giesecke et al. 1997). During 
2009, the reported IPD incidence was 17 per 100,000 individuals (www.smi.se; 
Swedish Institute for Infectious Disease Control). The incidence of pneumococcal 
infections shows seasonal variation and is highest during the winter months; in Sweden 
the majority of the cases occur during the period from October to April.   
Even in economically developed regions, the mortality rate for IPD is high. For 
example, studies in the United States have reported about a case-fatality rate for IPD 
between 20-40% (Austrian 1964; Hook et al. 1983; Mufson et al. 1982; Tomasz 1997). 
In Sweden, the case-fatality rate for pneumococcal pneumonia is 7-8%, whereas for 
IPD it averages 20-30% (Burman et al. 1985; Örtqvist 1999). Even in Western 
populations, the mortality rate may exceed 50% in certain high-risk groups (WHO 
2005).  
 
1.7.2 Risk factors associated with pneumococcal disease 
1.7.2.1 Age  
A major risk factor for acquiring a pneumococcal disease is age. The incidence is 
highest in individuals at the extremes of age, including children younger than two years 
and adults over 65 years of age. The increased risk of disease among children younger 
than two years of age is probably due to immature immunological response to the 
polysaccharide capsule and also a high colonization rate. Among elderly, the higher 
rates of underlying medical conditions and age-related immune dysfunction contribute 
to the higher rates of pneumococcal infection and death (Castle 2000).  
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1.7.2.2 Sex, race, and ethnicity 
Among people with pneumococcal disease, males are overrepresented among infants, 
children and adults (Klein 1981; Robinson et al. 2001). Also certain racial and ethnic 
groups seem to be at higher risk for acquiring pneumococcal disease. In Australia for 
example, the rates of IPD among Aborigines are between 4 to 30 times those reported 
for non-Aborigines (Roche et al. 2008; Torzillo et al. 1995; Trotman et al. 1995). 
Similarly, in the United States rates of IPD are higher for blacks and Native Americans 
than for whites and for persons of other racial backgrounds (Cortese et al. 1992; Pastor 
et al. 1998; Robinson et al. 2001; Rudolph et al. 2000). Contributing factors to these 
disparities in disease rates are inadequately examined, but may involve differences in 
living conditions and in prevalence of immunocompromising conditions. High rates of 
HIV infection among blacks in urban areas have been suggested as an important 
determinant, although among HIV-infected persons the risk of IPD is higher for blacks 
than for white (Dworkin et al. 2001; Gebo et al. 1996).  
 
1.7.2.3 Chronic medical conditions 
For persons with certain chronic medical conditions, for example HIV infection, 
asthma, cirrhosis, diabetes mellitus, functional or anatomic asplenia, chronic renal 
failure, hematological malignancies, and for persons taking immunosuppressive 
medications, the risk and severity of pneumococcal infection is increased (Burman et 
al. 1985; Lipsky et al. 1986).  
 
1.7.2.4 Living conditions 
Most pneumococcal infections occur sporadically despite the seasonal pattern, i.e., they 
are not a part of a recognized disease outbreak or cluster. However, occasionally there 
are reports about outbreaks of pneumonia, meningitis, and conjunctivitis caused by a 
single pneumococcal strain. Majority of the outbreaks occur in institutional settings 
such as jails (Hoge et al. 1994), hospital wards and care facilitates (Gleich et al. 2000; 
Nuorti et al. 1998; Subramanian et al. 2003), military units (Gray et al. 1999), 
homeless shelters (Mercat et al. 1991), and day-care centers (DCCs) (Cherian et al. 
1994; Craig et al. 1999). A common factor in these pneumococcal outbreaks is 
crowding which facilitates transmission of the organism to many susceptible persons.  
Another risk factor in living conditions seems to be the frequency of contact 
with preschool children. Day-care attendance has for example been strongly associated 
with an elevated risk of IPD for children, and exposure to preschool children appears to 
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increase the risk of pneumococcal disease in adults (Hendley et al. 1975; Levine et al. 
1999; Takala et al. 1995). 
 
1.7.2.5 Alcohol and tobacco use 
Heavy alcohol use and cigarette smoking have been observed to be common among 
otherwise healthy persons with pneumococcal disease and appears to be an important 
risk factor (Burman et al. 1985; Lipsky et al. 1986). Likewise, a study of 
immunocompetent adults between 18 to 64 years of age, reported that more than half of 
all cases of IPD were attributable to cigarette smoking (Nuorti et al. 2000).  
 
1.7.2.6 Preceding or coincident infection 
During the winter months in temperate areas when respiratory viral infections are most 
common, pneumococcal infections are more common (Dowell et al. 2003). In children, 
AOM often develops within days after onset of upper respiratory tract infections 
(Heikkinen et al. 2003), and adults with IPD is reported to have upper respiratory tract 
infections during the preceding month at a higher rate, compared with age-matched 
controls (Nuorti et al. 2000). There are also several lines of epidemiological evidence 
suggesting a relationship between influenza A virus and pneumococcal disease (Kim et 
al. 1996; O'Brien et al. 2000). Adults who have been experimentally infected with 
influenza A virus demonstrate increased susceptibility to nasopharyngeal colonization 
with pneumococci (Wadowsky et al. 1995).  
 
1.7.3 Molecular epidemiology  
In recent years, the use of molecular strain-typing methods has become increasingly 
integrated into the pneumococcal epidemiology. Examination of the molecular 
epidemiology of pneumococci gives deeper insights into spreading patterns and may 
help to develop and establish infection control measures. For example, molecular 
epidemiological studies of pneumococci have reported that a few clones (i.e., closely 
related isolates) are particularly successful in the global spread, being isolated over 
several years and contributing significantly to pneumococcal disease. Besides, the same 
clones are found in the nasopharynx of healthy children (Enright et al. 1999; Enright et 
al. 1998; Hermans et al. 1997; McGee et al. 2001).  
The major reasons for epidemiological surveillance are the increasing rates of 
resistant pneumococcal isolates over the world as well as the high incidence in 
pneumococcal infections. Both phenotypical and genotypical methods have been 
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developed and applied in epidemiological studies of pneumococci. For a long time, 
phenotypical approaches such as serotyping and antibiotic susceptibility profiles were 
the only techniques available to discriminate different pneumococcal strains. These 
methods are still very valuable, but have generally poor discriminatory power between 
clones. Therefore, several typing techniques based on genetic differences have been 
developed and applied in pneumococcal epidemiology. Examples of some methods 
used are various DNA fingerprinting methods such as ribotyping (Cherian et al. 1994; 
Kell et al. 1993; McDougal et al. 1992), DNA fingerprinting of the penicillin-binding 
proteins (PBPs) (Kell et al. 1993; Munoz et al. 1991; Munoz et al. 1992; Smith et al. 
1993), BOX fingerprinting (Hermans et al. 1995; Martin et al. 1992), pulsed-field gel 
electrophoresis (Lefevre et al. 1993; Lefevre et al. 1994), and restriction fragment 
length polymorphism (Hermans et al. 1995; van Steenbergen et al. 1995). The most 
recently developed method is multi-locus sequence typing which is based on the 
sequencing of around 450 bp internal fragments of seven housekeeping genes, resulting 
in a higher level discriminatory even by using a few numbers of loci (Enright et al. 
1998; Hanage et al. 2005).  
 
1.8 PREVENTION AND TREATMENT 
1.8.1 Antibiotic resistance 
The historically significant discovery of penicillin for almost hundred years ago 
revolutionized the medical treatment of patients since it was effective against many 
previously very serious infectious diseases. The widespread use of penicillin resulted in 
a dramatically reduction of the morbidity and mortality caused by various bacterial 
agents, including S. pneumoniae. Treatment options for pneumococcal infections are 
dependent on the site of infection and the degree of intrinsic drug resistance. For a long 
time, penicillin has been the drug of choice for all pneumococcal diseases because the 
bacterium was sensitive to antibiotic concentration easily achievable by either the oral 
or the parenteral course. However, during the last decades the therapy of pneumococcal 
infections has been complicated by the rapid emergence of antibiotic-resistant 
pneumococci. Examples of other antimicrobial agents used for pneumococcal 
infections include erythromycin, clindamycin, TMP-SMX, tetracycline, and 
vancomycin.  
However, already in 1967 the first penicillin resistant pneumococcal isolate was 
reported in Australia (Hansman 1967). Ever since then, the frequency of resistant 
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isolates has increased dramatically, and today penicillin resistant pneumococci and 
penicillin non-susceptible pneumococci (PNSP) have been identified all over the world. 
Also resistance to other antibiotics occurs among pneumococci, often in combination 
with penicillin resistance. The prevalence of multidrug-resistant pneumococci is 
increasing. In some countries, including the United States, Spain, France, South Africa, 
Israel and Japan, over 25% of the collected pneumococcal isolates are multi-resistant 
(Jacobs et al. 2003). It should be stressed that the definition of pneumococcal multi-
resistance varies between studies so making a comparison of proportions is difficult. 
According to Swedish Institute for Infectious Disease Control (www.smi.se), multi-
resistant pneumococci are defined as isolates resistant to penicillin and at least two 
other antibiotics, whereas the Centers for Disease Control and Prevention (or CDC; the 
United States government public health agency) defines multidrug-resistance to include 
any isolate exhibiting resistance two or more of the following classes of antibiotics: 
second-generation cephalosporins, macrolides, penicillins, tetracyclines, and 
sulphonamides (Thornsberry et al. 2008). However, multi-drug resistance is a serious 
clinical concern since it may limit the treatment possibilities considerably.  
In Sweden, the prevalence of resistant pneumococci is still a relatively minor 
problem in most regions. Only 3-6% of strains demonstrate decreased susceptibility to 
penicillin (paper IV; Borres et al. 2000; Molstad et al. 2008; Örtqvist 1999). However, 
certain regions such as the Stockholm area and southern Sweden suffer from higher 
prevalence of up to 10% of PNSP (Ekdahl et al. 1994). Also for other antibiotics, the 
resistance situation seems rather favorable; around 2-4% of the strains have been 
reported resistant to macrolides, 2% to tetracyclines, and 4-6% to trimethoprim-
sulphametoxazole (TMP-SMX) (paper IV; Örtqvist 1999).  
 
1.8.2 Emergence and spread of resistance in pneumococci 
A key role in determining how resistance emerges and spreads is the genetic basis 
(Figure 5). Several biological characteristics distinguish pneumococci from many other 
pathogens with acquired resistance. First, the primary source for pneumococcal 
spreading is asymptomatically carriage in the nasopharynx which may harbor both 
sensitive and resistant strains. Second, de novo resistance in pneumococci is rarely the 
result of single point mutation or plasmid carriage. Examples of important exceptions 
are TMP-SMX resistance and low-level fluoroquinolone resistance in which resistance 
is conferred by single point mutations in clinical isolates. However, resistance to the 
most major classes of antibiotics is acquired either by transformation or transfer via 
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conjugative transposons. Besides, the degree of resistance to certain antibiotics can vary 
widely in resistant strains. This graded phenomenon is measured as the minimum 
inhibitory concentration (MIC) of antibiotic necessary to inhibit growth, where 
different MICs are associated with different genetic alterations. Such biological features 
directly influence the population dynamics of pneumococcal resistance. 
 
 
 
FIGURE 5  Mechanisms for acquisition of antibiotic resistance determinants. Chromosomal mutations that reduce 
the sensitivity of the antimicrobial targets are common mechanism of resistance to several antimicrobials such as β‐
lactams, quinolones, and TMP. The horizontal spread of resistance to these antibiotics into different pneumococcal 
strains  is  probably  due  to  genetic  transformation,  whereas  the  resistance  determinants  for  macrolides  and 
tetracycline are typically borne on conjugative transposons which can be transferred either intra‐ or intercellularly.  
 
Asymptomatic carriers of pneumococci contribute more to pneumococcal spread than 
symptomatic individuals, in contrast to infectious diseases that do not include a carrier 
state. For most of the major antimicrobial classes, resistant pneumococci are spread 
mainly by clonal amplification. This means that infections with resistant pneumococci 
primarily are the result of acquisition of resistant strains from asymptomatic carriers in 
the community. Consequently, the major determinant for the global emergence of 
antibiotic resistance has been found to be the successful spread of a few resistant 
pneumococcal clones (Richter et al. 2002; Sjostrom et al. 2007).  
Interestingly, most clinical isolates associated with antimicrobial resistance 
belong to serotypes 6B, 9V, 9A, 14, 19F, and 23F (Schrag et al. 2000). It is still unclear 
why these serotypes have a higher probability of containing resistance determinants. 
However, a plausible explanation is that these serotypes are commonly isolated from 
children and thereby carried for longer durations and thus exposed to increased 
   27 
antibiotic pressure. Besides, transformation may play an important role in acquiring 
horizontally spread resistance determinants. Hitherto, the proportion of clinical isolates 
that are transformable in the laboratory has not been defined. Various capsular types 
may reduce or totally block transformation. Perhaps, differences in the competence 
regulon may limit the acquisition of resistance to particular clonal groups.   
 
1.8.3 Population-biological considerations 
Antibiotic therapy affects the pneumococcal population biology in several ways. The 
direct effect is mediated by inhibiting or killing those pneumococci that are susceptible 
to the drug at the achieved concentration. In a treated individual, the antibiotic-
mediated inhibition of susceptible strains will promote the growth of resistant strains 
given that pneumococcal strains compete to colonize nasopharynx (Lipsitch 2001b). 
Even if no resistant strain is present in the treated individual, inhibition of susceptible 
strains in an antibiotic-treated person could promote the spread of resistant strains in the 
community by reducing transmission of the susceptible strains with which the resistant 
ones compete (Lipsitch et al. 2002). Any used antibiotic that inhibits susceptible strains 
more than resistant ones will exert natural selection in favor of the strains against which 
it is less active. The relative efficacies against the susceptible and the resistant strains 
determine the degree of selection. 
Numerous epidemiologic studies have recognized recent antibiotic use as the 
strongest risk factor for the carriage and spread of non-susceptible S. pneumoniae at 
both community (Arason et al. 1996; Kristinsson 1995; Melander et al. 2000) and 
individual levels (Dagan et al. 1996; Dowell et al. 1997). In several countries, efforts to 
control antibiotic consumption have been undertaken in hopes of slowing the rising 
resistance trends in microorganisms. An important determinant in evaluating the effects 
from such efforts is the extent to which non-susceptible strains have any biological cost 
in competition with fully susceptible strains. That means, if no such fitness cost exist 
there is no disadvantage to being resistant and then there will be no selective pressure to 
drive down the rate of resistant strains even if antibiotic use were reduced to zero 
(paper II; Lipsitch 2001c). Moreover, in other microbes it have been observed that 
compensatory mutations occur which counteract the deleterious effects of resistance 
(Andersson 2003; Lipsitch 2001c). Hitherto, few studies have investigated this for 
clinically important resistance mechanisms in S. pneumoniae (Gillespie et al. 2002; 
Rieux et al. 2001). The successful global spreading of multi-resistant pneumococcal 
strains suggests, however, that if such fitness costs exist, they may be offset in certain 
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clones by association with other genetic features that enhances the fitness (Sjostrom et 
al. 2007). A simple reduction of the antibiotic consumption in the community may slow 
down the increase in resistance in pneumococci, but other interventions appears to be 
required to decrease the absolute level of resistance, for example large-scale vaccine 
programs (paper II). According to a previous modeling study, one of the most efficient 
ways to reduce pneumococcal transmission in the community is to reduce the group 
sizes in the DCCs (paper I). Such an intervention will most likely also result in fewer 
communicable diseases among children attending DCCs and thus, less antibiotic 
prescription.  
 
1.8.4 Mechanisms of resistance 
The emergence of antibiotic resistance observed in pneumococci all over the world 
during the last decades reflects dissemination of a few clones. The resistance rates vary 
significantly among different geographic regions and are influenced by patterns of 
antibiotic consumption, population density, and local prevalence of resistant strains. In 
this section, the mechanisms of action and resistance for some of the antibiotics often 
used for treating pneumococcal infections are described. Figure 6 summarizes the most 
common mechanisms mediating antibiotic resistance in bacteria.  
 
 
FIGURE 6  Overview of  the most  common  resistance mechanisms  in bacteria. Alteration of  target  sites  can  for 
example  be  methylation  of  the  bacterial  ribosomes  via  enzymes.  Another  mechanism  is  active  transport  of 
antibiotics out of the bacterial cell via efflux pumps, whereas inactivation of antibiotics can occur via degrading or 
altering enzymes.  
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1.8.4.1 Penicillin 
The most common mechanism of antibiotic activity is interference with bacterial cell 
wall synthesis. A majority of the cell-wall inhibiting antimicrobials are classified as β-
lactam antibiotics (e.g., penicillin, cephalosporin, cephamycins, β-lactamase inhibitors), 
called so because they share a β-lactam ring structure. The target proteins for β-lactams 
are bacterial enzymes that catalyses late steps in murein biosynthesis. Ever since the 
discovery of penicillin, it has been the drug of choice for pneumococcal infection. The 
popularity of penicillin is due to its high efficacy combined with an extremely low 
toxicity. However, the emerged penicillin resistance in pneumococci as well as in other 
pathogens has had a major impact on treatment regimes. The simplest mechanism for 
resistance against penicillin and other β-lactams is the production of β-lactamases. 
These enzymes are frequently encoded on plasmids and can therefore be readily 
transmitted between bacteria. Although pneumococci are naturally transformable, no β-
lactamase-producing isolate has been recognized to date (Klugman 1990). Instead, 
penicillin resistance in pneumococci is mediated by the alteration of penicillin target 
enzymes known as PBPs. These membrane-associated enzymes are believed to 
catalyze the terminal stages of murein synthesis and are inhibited by bonding with 
penicillin at their active site. The binding of penicillin to PBPs inhibits the cell wall 
synthesis and activates the LytA autolysin. Alterations in PBPs of resistant strains lead 
to decreased affinity to the drug so that higher penicillin concentrations are required for 
binding and inhibition of the enzyme (Hakenbeck et al. 1999b). There are six variants 
of PBPs found in susceptible strains: PBP1a, PBP1b, PBP2x, PBP2a, PBP2b, and 
PBP3. All six PBPs can occur as low affinity variants. Restructuring of the PBPs 
confers resistance; the level of resistance is determined by how many and to what 
extent the targets are modified. Several mutations in PBP2x or PBP2b lead to low 
affinity binding of β-lactams, providing a low-level resistance. These low-affinity 
forms of PBP2x and PBP2b are prerequisites for high-level β-lactam resistance as they 
results in high-level resistance in combination with low affinity variants of PBP1a 
(Hakenbeck et al. 1999b).  
In resistant clinical isolates of pneumococci, low-affinity PBPs are encoded by 
mosaic genes in which the PBP gene sequences are replaced by allelic variants that 
may differ by up to 25% in DNA sequence. It is believed that resistance has evolved in 
closely related streptococci via acquisition of point mutations in PBP genes prior to the 
transfer into S. pneumoniae. Genetic competence has obviously provided a valuable 
tool for the acquirement of resistance determinants that have evolved within the larger 
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streptococcal community gene pool. Studies have revealed that at least three PBPs are 
encoded by mosaic genes in high-level resistant clinical isolates: PBP1a, PBP2b, and 
PBP2x (Hakenbeck et al. 1999a).  
A phenomenon called penicillin tolerance has also been described in 
pneumococci (Tomasz et al. 1970). A tolerant strain has the ability to survive during 
therapy, but does not replicate and the growth is resumed after removal of the drug. 
Resistant strains seem to evolve more easily from tolerant ones without losing too 
much in fitness. It has, for example, been demonstrated that a penicillin tolerant strain 
could be transformed to resistant in one single step, in contrast to the non-tolerant 
parental strain (Novak et al. 1999). Also tolerance against vancomycin has been 
reported for pneumococcal strains (Gillis et al. 2005; Henriques Normark et al. 2001; 
Hidalgo et al. 2003; Sung et al. 2006). This is alarming since such strains could 
potentially develop into resistant ones (Novak et al. 1999). However, the exact 
background of tolerance has not been fully understood. From a clinical perspective, 
tolerance may lead to problem since the bacteria are not killed during therapy and will 
continue to grow as soon as the treatment is terminated. Besides, it is difficult to detect 
tolerant bacteria since they have the same MIC as susceptible strains.  
Ever since the first report about penicillin resistant in a clinical isolate of 
pneumococci in 1967 (Hansman 1967), the frequency of resistant isolates has increased 
and the prevalence varies widely between geographic regions. For example, a study 
including eight European countries reported penicillin resistance rates ranging from 
4.4% (Austria) to 61.9% (Spain) (Reinert et al. 2005).  An Asian study including 12 
countries revealed an average penicillin resistance rate of 29.4% where isolates from 
Vietnam showed the highest prevalence of penicillin resistance (71.4%) (Song et al. 
2004). According to population-based invasive pneumococcal surveillance during 2007 
in the United States, around 26% of the pneumococcal isolates were reported as PNSP 
(Gertz et al. 2010). As mentioned previously, studies performed in Sweden have 
reported relatively low rates of pneumococci with reduced susceptibility against 
penicillin (paper IV; Borres et al. 2000; Ekdahl et al. 1994; Molstad et al. 2008; 
Örtqvist 1999). 
 
1.8.4.2 Erythromycin 
The antimicrobial agent called erythromycin belongs to the group of macrolides which 
have a common structure formed by a large lactone ring. Erythromycins exert their 
effect by reversibly bind to the 23S rRNA of the bacterial 50S ribosomal subunit, 
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thereby blocking the polypeptide elongation during bacterial protein synthesis. In S. 
pneumoniae, the resistance to erythromycin is due to modification of the ribosomal 
target by methylation or mutation or by active efflux of the antibiotic. Ribosomal 
modification by methylation was the first resistance mechanism to erythromycin that 
was elucidated. It is secondary to the acquisition of an erm gene which is usually 
carried by transposable elements in pneumococci. This ribosomal methylase 
dimethylates 23S rRNA at a single site, adenine at position 2058, thereby causing a 
markedly reduced affinity of erythromycin for its target. Cross-resistance to macrolides, 
lincosamides, and streptogramin B antibiotics, referred to as MLSB-phenotype, is 
caused by the overlapping binding sites of the antibiotics. Expression of MLSB-type 
resistance can be either constitutive or inducible. Even if erm(B)  is widely 
predominant, it is not the only representative of the erm gene class in pneumococci. For 
example, the presence of erm(A), initially designated erm(TR), has been reported in 
rare cases (Syrogiannopoulos et al. 2001).  
Erytromycin resistance in pneumococci mediated by active efflux is usually 
caused by the presence of the mef(A) determinant. The mef(A) gene encodes an efflux 
pump that results in resistance only to 14- and 15-membered-ring macrolides, so called 
M-phenotype. Isolates harboring the mef(A) gene normally display less marked 
resistance to erythromycin, whereas isolates with the erm(B) determinant usually show 
a high-level resistance. Other macrolide resistance mechanisms detected in 
pneumococci include mutations in a highly conserved region of domain V of 23S 
rRNA and in ribosomal proteins L4 and L22 (Canu et al. 2002; Tait-Kamradt et al. 
2000a; Tait-Kamradt et al. 2000b). 
The first erythromycin resistant isolates of S. pneumoniae was reported in 1967 
in the United States and subsequently worldwide (Klugman 1990; Weisblum 1967). 
Although macrolide resistance in pneumococcal strains is prevalent, it varies markedly 
in different countries (Pallares et al. 2003). For example, in France and Italy over 40% 
of isolates have been found resistant (Schito et al. 2000), in contrast to only ~3% of 
strains in Norway (Littauer et al. 2005) and Sweden (paper IV). The distribution of the 
two dominating resistance types, erm(B) and mef(A), varies, but MLSB is more 
prevalent in Europe (Montanari et al. 2001) whereas the efflux type predominates in the 
United States and Canada (Johnston et al. 1998). 
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1.8.4.3 Clindamycin 
Clindamycin is a lincosamide antibiotic and its mechanism of action resembles that of 
macrolides. This agent binds to the 23S rRNA subunit of the bacterial ribosome and 
prevents translocation of the peptidyl-tRNA from the A-site to the P-site during protein 
synthesis. The ribosome therefore releases an incomplete protein. Pneumococcal 
isolates carrying the erm(B) gene, and thereby exhibiting the MLSB-resistance 
phenotype, are resistant to clindamycin. As described previously, the erm(B) encoded 
methylase alters the ribosomal binding site which confer high-level cross-resistance to 
macrolides, lincosamides, and streptogramin B antibiotics.  
 
1.8.4.4 Trimethoprim-sulphametoxazole  
Sulphonamides (SMX) were the first class of antimicrobial agents introduced into 
clinical use, which occurred in 1935. Trimethoprim (TMP) was introduced in 1962, and 
the combination TMP-SMX was brought into clinical use in 1968. These two agents act 
synergistically to inhibit enzyme systems involved in the bacterial synthesis of 
tetrahydrofolic acid.  Resistance to TMP-SMX in a clinical pneumococci isolate was 
first identified in 1972 (Howe et al. 1972). Today, TMP-SMX resistance is very 
commonly found among pneumococci. Rates of TMP-SMX resistance appears to be 
higher among carriers than in clinical isolates (Klugman 1990). For example, TMP-
SMX resistant strains collected from healthy carriers in Spain comprised 79.2% of 
isolated pneumococci (Perez et al. 1987), whereas in clinical specimens between 37.7 -
51.7% of the strains showed TMP-SMX resistance (Klugman 1990; Perez et al. 1987). 
Sweden appears to be a region with relatively low prevalence of TMP-SMX resistant 
pneumococci; reported rates range from 1.7% to 4% among clinical isolates (paper IV; 
Zackrisson et al. 1981).  Resistance to TMP in pneumococcal isolates is mediated by 
multiple mutations in a gene encoding a reductase enzyme, while isolates with reduced 
susceptibility carry a single mutation (Maskell et al. 2001). Similarly, altered 
chromosomal reductase genes can lead to resistance to sulfonamides. It has been shown 
that isolates which are resistant to TMP rarely are sensitive to TMP-SMX (Adrian et al. 
1997). Hence, TMP-SMX appears to correlate more strongly with TMP resistance than 
SMX resistance.   
 
1.8.4.5 Tetracycline 
In 1948, tetracycline antibiotics were introduced into medicine and were then quickly 
accepted since they offered a broad spectrum of activity. The action of tetracycline is 
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presumed to be mediated by binding to a site on the bacterial 30S ribosomal subunit 
and thereby inhibiting the elongation phase of protein synthesis (Connell et al. 2003a). 
In S. pneumoniae, tetracycline resistance is a result of acquisition of one of two 
resistance determinants, tet(M) or tet(O). These genes encode ribosomal protection 
proteins. Thus far, ribosomal protection is the only mechanism for tetracycline 
resistance described. It appears that Tet(M) and Tet(O) confer resistance by promoting 
the release of the drug from its inhibitory site on the ribosome (Burdett 1996; Connell 
et al. 2003b). The most commonly found tetracycline resistance gene in pneumococci, 
tet(M), is located on two transposons called Tn1545 and Tn5253, whereas the tet(O) 
gene, which is chromosomally situated, probably have been acquired trough 
transformation (Widdowson et al. 1998). In streptococci, tet(O) can be conjugatively 
transferred on plasmids to other Gram-positive bacteria; however, plasmids are not 
common in pneumococci (Widdowson et al. 1998).  
 
1.8.4.6 Fluoroquinolones 
Fluoroquinolones acts by interfering with bacterial DNA metabolism through inhibition 
of two essential bacterial DNA topoisomerases, DNA gyrase and topoisomerase IV. 
These enzymes are involved in the regulation of chromosome supercoiling and 
decatenation. A cleavable complex is formed between quinolones and DNA 
topoisomerases which results in irreversible double-strand DNA breaks, leading to cell 
death (Drlica et al. 1997; Khodursky et al. 1998). Fluoroquinolone resistance involves 
two main mechanisms, target modification and increased active efflux. Generally, low-
level resistance is caused by mutations in the quinolone resistance-determining region 
in either of the target genes, whereas high-level resistance requires additional mutations 
in the quinolone resistance-determining region of the second target (Pan et al. 1996; 
Pan et al. 1997; Pan et al. 1998). In clinical isolates of pneumococci, quinolone 
resistance is primarily due to mutated subunits C of topo IV and/or subunits A of 
gyrase (Varon et al. 2000). The other phenotype of resistance is caused by an increased 
active efflux of the drug mediated directly by adenosine triphosphate hydrolysis or by 
the proton motive force, which confer a moderate level of resistance to levofloxacine, 
norfloxacine, and ciprofloxacine (Varon et al. 2000).  
Ciprofloxacine has been in widespread clinical use for bacterial diseases over a 
decade; however, because of its low activity against Gram-positive bacteria it is not an 
ideal antibiotic for respiratory infections. Newer quinolones (e.g., gatifloxacin, 
gemifloxacin, and moxifloxacin) have shown an enhanced activity against the majority 
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of respiratory pathogens and are therefore more widely used. There are studies 
reporting about rapidly emerging frequency of quinolone resistance in pneumococci 
(Deshpande et al. 2006; Pallares et al. 2003), whereas others, in contrast, report about a 
low prevalence of quinolone resistant strains (Davies et al. 2008; Pletz et al. 2010). 
 
1.8.4.7 Vancomycin 
Vancomycin acts by inhibiting the synthesis of the bacterial cell wall. For sensitive 
bacteria, exposure to vancomycin leads to arrest of bacterial growth. At the same time, 
autolysins are activated and subsequently, cell lysis occurs. Vancomycin is used more 
frequently to treat severe, invasive infections caused by multidrug-resistant 
pneumococci. Although no vancomycin-resistant isolates have been recognized 
hitherto, vancomycin-tolerant pneumococcal strains failing to die rapidly and thereby 
causing relapsing disease have been reported over the world (Gillis et al. 2005; 
Henriques Normark et al. 2001; Hidalgo et al. 2003; Sung et al. 2006). Strains that do 
not undergo autolysis after treatment with vancomycin show an increased survival and 
are termed tolerant. The exact vancomycin tolerance mechanism in pneumococci 
remains to be determined, however, it appears to be a multifactorial phenomenon 
arising from the effects of the bacterial capsule (Fernebro et al. 2004), the autolysin 
LytA (Tomasz et al. 1970), and the ABC transport system Vex123 (Haas et al. 2005; 
Haas et al. 2004).  
 
1.8.5 Clinical relevance of resistance  
The clinical relevance of antibiotic resistance in vitro among pneumococci is still not 
fully elucidated despite increasing resistance rates over the world. There is a debate 
whether increasing resistance to β-lactams, macrolides, and other antimicrobial agents 
has been followed by increased rates of treatment failure and mortality. Although rising 
resistance rates, these agents are still used as first-line empirical therapy in the 
outpatient setting. A reason for this may be the infrequency with which clinicians 
recognize clinical failures. It appears like the present in vitro definitions of drug 
resistance in pneumococci are not appropriate for all types of pneumococcal infections. 
The clinical failures observed with the emergence of resistance to some classes of 
antimicrobials and the successful continued use of other agents despite emerging 
resistance can be explained by the use of pharmacodynamics. The impact of resistance 
on bacterial eradication and clinical outcome can be examined by measuring 
antimicrobial susceptibility (i.e., MIC) and compare it to the achievable unbound 
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fraction of drug at the infection site. Thereby, measures of the ability of the antibiotic to 
kill or inhibit bacterial growth are obtained (Craig 1998).  
To most clinically important antibiotics classes, most pneumococcal resistance 
is high-level resistance. This means that the MICs for resistant strains are well above 
clinically achievable concentrations. A major exception is, however, pneumococcal 
resistance to penicillin. The definition for PNSP is a MIC-value ≥0.125 µg/ml 
(www.smi.se) whereas a strain for which the MIC is ≥2 µg/ml is considered highly 
resistant (www.srga.org; The Swedish Reference Group for Antibiotics), and many β-
lactam agents can reach concentrations considerably higher than these thresholds. 
Therefore, it is possible for penicillin and other β-lactams to inhibit strains classified as 
resistant.  
Pneumococcal infections due to strains with indeterminate resistance to β-
lactam have not been associated with either treatment failure or increased mortality 
(Heffelfinger et al. 2000). Current levels of resistance to penicillin and cephalosporin 
appear to have little, if any, clinical significance in non-meningeal infections. For 
treatment of pneumonia caused by indeterminate resistant strains of pneumococcus 
(0.06≤ MIC <2; www.srga.org), penicillin and its derivatives in standard doses are still 
effective. In the absence of immediate hypersensitivity reactions, penicillin can be 
safely administered in doses high enough to overcome these intermediate resistance 
mutations. For example, treatment failures of β-lactam therapy in pneumococcal 
pneumonia have never been reported for penicillin, and only rarely reported for other 
agents that are less active against pneumococci (Buckingham et al. 1998; Daum et al. 
1994; Dowell et al. 1999; Fuller et al. 2005; Pallares et al. 1995; Sacho et al. 1987). 
This is in contrast to the numerous reports of clinical failures in patients with 
pneumococcal meningitis caused by isolates with penicillin MICs ≥0.12 µg/ml. Only 
when the strain is known to be fully susceptible to penicillin, it can be used for treating 
pneumococcal meningitis. As antimicrobial penetration into the cerebrospinal fluid 
(CSF) is constrained by the blood-brain barrier, even strains with indeterminate 
resistance are associated with clinical failure. Consequently, the penicillin resistance 
breakpoint for pneumococci in meningeal infections is defined as MIC ≥0.06 
(www.srga.org).  
For the macrolides, there are several case reports documenting treatment failure 
against resistant strains, and studies suggesting an association between macrolide 
resistance and breakthrough bacteremia (Fuller et al. 2005).  Noteworthy is that it has 
been observed that macrolide resistance due to mutations in genes encoding rRNA 
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and/or ribosomal proteins may result in the emergence of resistance during therapy and 
subsequently clinical failure (Butler et al. 2003; Kays et al. 2002; Musher et al. 2002). 
Furthermore, therapy failures have been recorded repeatedly for fluoroquinolones, 
TMP-SMX, and tetracycline for treatment of pneumonia caused by resistant S. 
pneumoniae (Davidson et al. 2002; Empey et al. 2001; Hansman et al. 1967; Klugman 
et al. 1986; Linares et al. 1983; Perez-Trallero et al. 1990; Perez-Trallero et al. 2003; 
Urban et al. 2001).  
 
1.8.6 Pneumococcal vaccines 
Today, two vaccine formulations are available to prevent pneumococcal infections. The 
immune responses induced by these two different pneumococcal vaccine formulations 
are further discussed in section 1.6.2. The first developed vaccine has been on the 
market since 1977 and is a polysaccharide vaccine consisting of the 23 most common 
capsular serotypes causing invasive disease in the developed world. However, its 
effectiveness is hampered by poor responses in elderly people, immunocompromised 
patients, and in very young children (<2 years) as this widely used vaccine only induces 
T-cell-independent B-cell responses. Therefore, conjugate vaccines have been 
developed where a carrier protein called CRM197, a non-toxic recombinant variant of 
diphtheria toxin, is coupled to the polysaccharides which results in a T-cell-dependent 
response causing B-cells to produce antibodies recognizing the polysaccharide 
antigens. Pneumococcal conjugate vaccines (PCV) have now been in use for almost 10 
years, and several types of PCVs have been developed. The heptavalent conjugate 
vaccine (PCV-7) targets the serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. These 
serotypes are together responsible for between 60-90% of pediatric infections in 
developed countries (Eskola et al. 2001). Both the compositions of the 23-valent 
polysaccharide vaccine and the 7-valent conjugate vaccine were based on the serotype 
prevalence mainly in the United States. This may cause problems with coverage rates 
of the vaccines in certain settings and countries. In the least-developed countries, 
outbreaks of serotypes 1 and 5, which not are included in the PCV-7, are important 
cause of childhood disease (Reinert et al. 2010). Europe and the United States show a 
similar serotype distribution with only minor differences. By including the serotypes 1 
and 5, a 9-valent PCV was developed; and by further addition of serotype 7F, a 10-
valent conjugate vaccine could be produced. This was followed by an 11-valent PCV 
which also included serotype 3. Moreover, the latest PCV formula gives protection 
against 13 serotypes; besides the ones already mentioned it also targets types 6A and 
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19A. In the United States, PCV-7 has been in use since 2000 and during that time 
severe pneumococcal disease has been reduced with nearly 80% among children under 
the age of five years (Kyaw et al. 2006). PCV-7 is now being replaced with PCV-13 in 
the United States. In Sweden, the heptavalent PCV is included in the national 
immunization program for children since 2009. PCV-7 is estimated to cover 74% of the 
strains circulating among children younger than two years in Sweden (Hedlund et al. 
2003). Just recently, PCV-13 was approved also for use in Europe, and it has potential 
to give over 90% protections against pneumococcal infections (Reinert et al. 2010). 
A significant attribute of the PCVs has been the degree of herd immunity (i.e., 
protection of non-vaccinated persons) it produces. In contrast to polysaccharide 
vaccines, the PCVs also protect against non-invasive pneumococcal infections (e.g., 
AOM and sinusitis) and against pneumococcal carriage. The frequency of IPD in non-
vaccinated siblings and in adult contacts has been reported to decline after PCV 
implementation (van der Poll et al. 2009). Young children constitute the main reservoir 
for pneumococci and thus elimination of the carrier state in children reduces 
transmission risks to the rest of people.  
A desired effect of a large-scale use of PCV is decreased prevalence of vaccine 
serotypes mainly associated with antibiotic resistance. Five of the serotypes (6B, 9V, 
14, 19F, and 23F) included in PCV-7 are those most often associated with penicillin 
resistance (Schrag et al. 2000). Kyaw et al. reported that IPD caused by resistant 
isolates were reduced after the PCV-7 introduction in the United States (Kyaw et al. 
2006), which suggests that vaccination may decrease the prevalence of resistant 
pneumococci. These results are supported by a study in France that reported a reduction 
in the carriage of PNSP following PCV-7 introduction (Cohen et al. 2009). However, a 
study from Portugal indicates that vaccination must be combined with a decreased use 
of antibiotics in order to reduce the resistance rates in pneumococci (Frazao et al. 
2005). In short term, the vaccine may help to control the spread of resistant 
pneumococci, but over time the rate of nasopharyngeal carriage of non-vaccine types 
will probably increase due to serotype replacement. Then the selective pressure 
imposed by antibiotic use must be reduced to counteract high rates of resistant non-
vaccine serotypes.   
Several studies have been performed before and after vaccine implementation to 
monitor the effectiveness and the serotype distribution. A study performed in 
Netherlands two years after introduction of PCV-7 reported a decrease in vaccine-
serotype IPD by 90% in children of age eligible for PCV-7, however, simultaneously, 
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non-vaccine serotype IPD increased by 71% (Rodenburg et al. 2010). For other age 
groups the IPD frequency did not change. Isaacman et al. reviewed several studies from 
studies in Europe from 1990 to 2008  and they observed that effective use of PCV-7 
causes a general decline in IPD in young children and also a decreased prevalence of 
vaccine serotypes (Isaacman et al. 2010). In conclusion, several other studies have 
shown a general decrease in IPD after vaccine implementation, whereas non-vaccine 
serotypes have increased. Since PCV-7 introduction, the most common IPD isolates in 
Europe are 1, 19A, 3, 6A, and 7F (Isaacman et al. 2010), which are included in the 
PCV-13 formula. In the United States, the serogroups 15 and 33 have become an 
increased cause of IPD in children after PCV-7 implementation (Gonzalez et al. 2006). 
However, IPD caused by vaccine serotypes in children were reduced by 75% after 
vaccine introduction in the United States (Kaplan et al. 2004). The same study reports 
an increased frequency of serogroups 15 and 33, as well as increased penicillin 
resistance among non-vaccine serotypes.  
The shortcomings of the polysaccharide and conjugate vaccines have prompted 
extensive research aimed at development of vaccines based on pneumococcal proteins 
that contribute to virulence and are common to all serotypes. Such serotype-
independent vaccine should be highly immunogenic and elicit an immunological 
memory in young children, who respond well to T-cell-dependent protein antigens. 
Besides, an optimal antigen should have a low antigenic variability. Several candidate 
protein antigens have been examined for vaccine potential. For example pneumococcal 
surface protein A, pneumolysin, pneumococcal surface protein C (also called CbpA), 
pneumococcal surface antigen (Tai 2006) and pneumococcal neuraminidase (Simell et 
al. 2006) have been proposed as vaccine antigens. To achieve the advantages of herd 
immunity, an optimal vaccine formula also needs to protect not only against 
pneumococcal disease but also carriage.  
 
1.8.7 Influenza vaccination 
Influenza vaccination is an important measure to reduce the risk for pneumonia, 
especially in elderly. Likewise, the incidence for pneumococcal pneumonia appears to 
be decreased by influenza vaccination. A Swedish study reported that influenza 
vaccination gives a 58% protective efficacy against IPD among elderly; however, the 
number of patients included was too small to achieve a statistical significance 
(Christenson et al. 2004). 
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1.9 THEORETICAL BIOLOGY  
Applying mathematics in natural sciences and other disciplines have a long history. Just 
recently there has been an explosion of interest in the use and application of theoretical 
approaches such as mathematics and computation within biology and medicine. There 
are numerous reasons for this, for example the explosion of data-rich information sets 
due to the genomics revolution, which are difficult to understand without the use of 
analytical tools, and an increase in computing power which enables calculations and 
simulations to be performed that were not previously possible. Besides, there is an 
increased interest in in silico experimentation due to ethical considerations, risks, 
unreliability, and other complications involved in human and animal research.  
A novel branch in this research area is systems biology, which can be described 
as a biology-based interdisciplinary study field focusing on complex interactions in 
biological systems. It applies a new holistic perspective aiming at putting together 
rather than taking apart. Systems biology encompasses a wide range of fields from 
modeling of biological system to biostatistics and computational genomic. Systems 
biologists investigate the behavior and relationships in a certain biological system while 
it is functioning, and want to illuminate biological processes at the level of systems.  
 
1.9.1 Mathematical modeling of biological systems 
Modeling biological systems is a highly relevant task within systems biology. Models 
can be used to make predictions and to conduct experiments in silico. Moreover, the in 
silico design may reduce the time and costs needed to develop medical drugs and also 
the number of animal experiments. A model is a tool which helps better understand the 
biological phenomenon studied.  
Any model can be defined as a simplified representation of certain aspects of a 
real system. A model constructed using mathematical concepts, such as equations and 
functions, is referred to as a mathematical model. Creating mathematical models means 
moving from the real world into an abstract world of mathematical concepts which is 
where the model is created. The model is then manipulated, solved and analyzed in 
several ways using mathematical, computational, and statistical techniques. At last, the 
real world can be re-entered with the solution to the mathematical problem, which is 
then translated into a useful explanation to the real problem. For a particular problem 
there is not only one right and proper model; many different models can be developed 
for dealing with the same problem. However, some models may be better than other in 
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the sense that they are more useful or more accurate. In general, the success of a model 
depends on how easily it can be used and how accurate its prediction is. Any model 
will also have a limited range of validity and should not be applied outside its range. A 
mathematical or computational model of a biological system is developed based on 
data and knowledge of the function and relationships within the system of interest 
(Figure 7).  
 
 
 
FIGURE 7  The  process  of  knowledge  generation  in  systems  biology.  Adapted  from  Reiss,  R.,  Systems  of  Life. 
Systems Biology. (2002) Druckerei Hörning, Heidelberg.  
 
The model permits hypotheses about the characteristics and behavior of the system to 
be derived. These hypotheses can then be verified in parallel in in silico and in vivo/in 
vitro experiments. The in silico simulations will generate new data that allow validation 
of the hypotheses. In parallel, in vitro experiments will produce new biological data 
which will also help to verify the hypotheses. This iterative work process leads to new 
biological knowledge. 
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1.9.2 Modeling approaches 
There are several different modeling approaches suitable for different applications. 
These approaches can be categorized broadly as being deterministic or stochastic. A 
deterministic model is one in which each variable changes according to a mathematical 
formula, without any room for random variation. In such models, a given input will 
always generate the same outcome. Examples of deterministic approaches include 
difference equations (discrete time, continuous state space), ordinary differential 
equations (ODE; continuous time and state space, no spatial derivatives), and partial 
differential equations (continuous time and state space, spatial derivatives).  
The deterministic modeling approach contrasts with the stochastic 
(probabilistic) one where randomness is present and variables states are described using 
ranges of values in the form of probability distributions. Approaches that encompass 
stochastic processes are Markov models and Bayesian networks.  
 
1.9.3 Models of infectious disease epidemiology  
For a long time, mathematics has been an important tool in infectious disease 
epidemiology. Models within infectious disease epidemiology can be used for 
predictions about the future, but also aid us in understanding complex networks by 
providing a simplified picture of a situation or a progression. They may help us to 
recognize which determinants are the most important factors of the progression and 
therefore which determinants we should examine more in detail. Infectious disease 
models permit the conductance of in silico experiments that would be practically 
feasible or unethical to perform in a controlled experiment in real life. For example, we 
cannot intentionally introduce pathogen agents into populations or withhold potentially 
lifesaving interventions for the sake of scientific study. The use of mathematical 
models of disease transmission provides a way around this difficulty, and thereby 
makes it possible to systematically evaluate intervention strategies such as vaccination 
and quarantine.  
The progress of an epidemic in a large population has traditionally been 
modeled using compartmental models. In such models, the population diversity is 
reduced to a few key characteristics which are relevant for the infection under 
consideration.  As example, we can use childhood diseases, such as measles, mumps, 
and rubella, which usually provide long-lasting immunity after infection. The 
population can then be subdivided into those who are susceptible to the disease, those 
who are currently infected or infectious, and those who have recovered and are immune 
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(Nichol et al. 2010). Such subdivisions of the population are called compartments. 
Standard convention labels these three compartments S (susceptible), I (infected), and 
R (recovered), and therefore this model is referred as the SIR model. Each individual of 
the population typically progresses from susceptible to infectious to recovered as 
shown in Figure 8. Between susceptible and infected, the transition rate is β. This rate 
considers the probability of acquiring the disease in a contact between a susceptible and 
an infected individual (Nichol et al. 2010). The transition rate from infected to 
recovered is denoted v, the recovery rate. If an infected person becomes immune after 
time D, the duration of the disease, then v = 1/D. For example, if the disease duration, 
D, is 7 days, then 1/7 of all the infected individuals recover each day and move from 
the infectious compartment into the recovered group.  
 
 
FIGURE 8  Diagram  of  the  SIR  model.  The  modeled  population  is  subdivided  into  three  compartments  as 
represented by the boxes whereas the arrows indicate transition between the compartments. 
 
However, some of the assumptions underlying the SIR model are seriously unrealistic. 
For example, it assumes that every people in the population will meet every other with 
equal probability. This “law of mass action” is actually derived from chemistry and 
describes how substances enter into chemical reactions. Among individuals there will 
always be some contacts that are likely or common, and others that will never occur. 
The contact pattern in the society is far from homogenous and therefore, most 
infections spread more slowly than predicted by the SIR model (Giesecke 2002).  
Another unrealistic assumption is that only one type of contact exists as given by β, 
although diseases may spread along different routes with varying probabilities of 
transmission to occur.  
Such a deterministic modeling approach implies that the progression and size of 
an epidemic are always determined by the defined transition rates, and will generate the 
same result every time. For most epidemics, however, it is intuitively clear that chance 
may play a role. Probabilistic models are often more complex than deterministic ones, 
and is generally evaluated using a computer. A simulated epidemic is then run repeated 
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times. Each run produce different results due to chance and these results can be 
averaged to find the most likely outcome.  
One type of a probabilistic approach is contact network modeling which has the 
advantage that it captures realistic diversity in contact patterns which are ignored by 
most compartmental models. A realistic network model of the contact patterns is then 
created and the spread of an infectious agent can be predicted based on intrinsic 
features of the pathogen and structural properties of the network. Nonetheless, the main 
problem for both deterministic and probabilistic models is the lack of good quantitative 
data of infections (Giesecke 2002). Besides, the contact pattern in the population is 
sometimes unknown and very complicated to model.  
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2 AIMS 
The general aim of this thesis was to learn more about emergence and spread of 
antibiotic resistant pneumococci using both theoretical and empirical methods.  
 
2.1 PAPER I 
The increasing prevalence of antibiotic resistant pneumococci is primarily due to the 
spread of resistant strains belonging to few clones. Thus, the aim of paper I was to 
evaluate measures aiming to control transmission of S. pneumoniae in the community.  
 
2.2 PAPER II 
The effects of reduced penicillin consumption on the pneumococcal population 
dynamic are not fully understood. In paper II, the impacts of penicillin consumption 
and between-strain competition on the spreading of susceptible and non-susceptible 
pneumococcal strains in the community were assessed. 
 
2.3 PAPER III 
Competence for genetic transformation is an important mechanism for spread of 
resistance genes in pneumococci. Understanding the regulation of competence is 
essential to prevent horizontal spread of resistance genes. Paper III aimed at studying 
the dynamic and regulation of competence in pneumococci.  
 
2.4 PAPER IV 
Invasive infections caused by antibiotic resistant pneumococci constitute a worldwide 
problem. The aim of paper IV was to examine the resistance pattern in invasive 
clinical isolates of S. pneumoniae collected in southwest Sweden during 1998-2001, 
and correlate resistance to clinical parameters.  
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3 MATERIAL AND METHODS 
3.1 COLLECTION OF STRAINS 
During 1998-2001, pneumococcal isolates from blood and CSF were collected 
prospectively from the six laboratories of clinical bacteriology in the counties of Västra 
Götaland and Halland in south-west Sweden. All 13 hospitals in the counties were 
served by these laboratories. In total, 839 clinical strains were isolated from patients 
suffering from invasive pneumococcal infection, and 827 strains could be revived for 
susceptibility testing.   
 
3.2 CLINICAL DATA 
In paper IV, including 827 invasive pneumococcal isolates, clinical data were 
available. Information about age, gender, mortality, underlying disease, known abuse of 
alcohol and/or narcotics, clinical manifestation, year of isolation, geographic area were 
recorded. A more detailed description of the clinical characteristics and serotype 
distribution on the same material has been published in a previous report (Berg et al. 
2006). Complete records of clinical data were obtained from individual hospital notes 
for 818 patients. For the remaining nine patients, date of culture, source of isolate, age 
and gender were known.  
 
3.3 METHODS 
3.3.1 Serotyping 
All pneumococcal isolates were serotyped with the quellung reaction at the WHO 
Collaborating Centre for Reference and Research on Pneumococci, Statens Serum 
Institute, Copenhagen, Denmark (Lund 1978).   
 
3.3.2 Antibiotic susceptibility  
The pneumococcal isolates were tested for antimicrobial susceptibility using the 
epsilometertest (E-test®) to determine MIC to penicillin G, erythromycin, clindamycin, 
tetracycline, moxifloxacin, and TMP-SMX. The E-test® (AB Biodisk, Sweden) is an 
antibiotic gradient strip that is applied to an inoculated agar plate and results in an 
elliptical zone of inhibition that intercepts the graded strip, generating a quantitative 
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result. The gradient ranges for the antimicrobial agents included in this study were as 
follows: penicillin G 0.002-32 µg/ml; erythromycin 0.016-256 µg/ml; clindamycin 
0.016-256 µg/ml; tetracycline 0.016-256 µg/ml; moxifloxacin 0.002-32 µg/ml; and 
TMP-SMX 0.002/0.038-32/608 µg/ml. The isolates were categorized as sensitive (S), 
indeterminate (I) or resistant (R) for all agents according to the SRGA system of 
species related breakpoints (www.srga.org).   
 
3.3.3 Methodological considerations 
E-test® appears to be a reliable method for determination of MICs for a variety of 
antibiotics among pneumococci (Jacobs et al. 1992). However, there are 
methodological problems associated with this test for estimating the MICs of 
pneumococci to cotrimoxazole (Jorgensen et al. 1991) since  poor interlaboratory 
reproducibility have been reported (Fuchs et al. 1997; Lovgren et al. 1999). 
 
3.4 THEORETICAL METHODOLOGY 
All simulation procedures in paper I and II were programmed in MATLAB 
(Mathworks Inc.), whereas SPSS (SPSS Inc.) were used for the statistical analyses. In 
paper III, the calculations were performed with MATLAB and Mathematica (Wolfram 
Research Inc.).  
 
3.4.1 Contact network epidemiology 
In this section, the methodology underlying contact network modeling is discussed 
briefly. The method of contact network epidemiology used in paper I and II can be 
divided into three steps. First, a realistic network model of the contact patterns at an 
appropriate scale is created. Next, the infection is spread computationally through the 
population based on intrinsic characteristics of the microbe and structural properties of 
the network. Thereafter, the network is manipulated to model control strategies. The 
epidemiological consequences of such manipulations can then be analyzed. Figure 9 
graphically visualizes the network concept.  
The patterns of interactions that may lead to transmission of an infectious disease are 
captured by a contact network model. Herein, each individual translates into a vertex 
and contacts among people into edges that connect appropriate vertices. For example, 
one may like to model the contacts between persons in a hospital that may result in 
respiratory disease transmission or the sexual interactions within a high school that 
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might lead to sexually transmitted disease transmission. When simulating the spread of 
infectious agents in network models, an infection may first appear either at randomly 
chosen vertices or at predetermined vertices. Disease will propagate with certain 
transmission probabilities through the network as defined by the edges. The vertices 
will remain infected and infectious for some period of time, during which they have the 
potential to transmit disease to each of their contacts. Both the level of contagion and 
the structure of the contact network influence the percolation of disease through a 
network. The disease will traverse some but not all of the edges.  
 
 
FIGURE 9  Graphic  illustration of the network concept. The dots represent  individuals  in the population, and the 
quadratic boxes are households whereas the rectangles are DCC and school, respectively. Individuals within same 
household have  contact with each other, while  individuals within  same DCC or  school only have  contact  if  they 
belong to the same day‐care group or class. Disease transmission can only occur via edges, i.e., contacts, between 
vertices, i.e., individuals. The edges are bidirectional, i.e., disease may be transmitted in both directions.  
 
By manipulating the contact network model, we can evaluate the impact of control 
strategies. There are several forms of interventions. One is transmission-reducing action 
and includes interventions that in one way or another decrease the probability of 
transmission (e.g., improved hand hygiene, disinfection, face mask etc.). Another way 
is immunizing interventions such as prophylactic medication and vaccination. More 
specifically, different vaccine strategies (e.g., vaccinating specific groups of individuals 
based on risk factors such as age or health, general vaccination) can be assessed by 
simply removing the immunized individuals from the network, whereas isolation of 
infected persons belongs to contact-reducing interventions and can be modeled by 
removing appropriate edges between vertices.  
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3.4.2 Systems of ordinary differential equations 
An ODE is a mathematical equation for an unknown function x of one variable that 
relates the values of the function itself and its derivatives of various orders. In paper 
III, a dynamical system of non-linear ODEs describing the components involved in the 
competence-evoking quorum sensing pathway was constructed. This model was 
derived in a biology-driven way, which means that the underlying biology was studied 
and then translated into reactions and equations.  
The main components in ODE models are the objects and the actions. The 
objects may represent model entities such as molecules, cells or organs, while the 
actions may represent activation, inhibition, or migration. ODEs describe the rates of 
changes (actions) of quantities (objects). In the competence model, the variables 
denoted the total amounts of the components in a population of n cells, whereas the 
parameters represented rates of changes.  
 
3.4.3 Parameter analysis 
Parameter analysis can be used to examine how sensitive a model is to changes in the 
value of the parameters or the structures of the model. Usually, parameter analysis is 
performed by a series of tests in which different parameter values are set in order to 
observe how a change in the parameter causes a change in the model outcome. 
Parameter analysis is a technique for systematically changing parameters to determine 
the effects of such changes. Dependent on the current model type, there are numerous 
procedures of how to change the parameter values and also of how the results are to be 
analyzed.  
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4 RESULTS AND DISCUSSION 
This thesis aimed at investigating emergence and spread of antibiotic resistant S. 
pneumoniae using both theoretical and empirical methods. In paper I, an individual-
based network model was developed and used to evaluate the efficacy of interventions 
aiming to control pneumococcal transmission in the community. A similar modeling 
approach was applied in paper II wherein the impact of penicillin consumption on 
pneumococcal spreading in the society was investigated. Although clonal spreading 
serves as the primary mechanism responsible for the emergence of resistance in 
pneumococci, the pneumococcal feature of competence for genetic transformation is 
also of importance. In paper III, the regulation of the competence-evoking quorum 
sensing network in pneumococci was studied using theoretical means. Finally, in paper 
IV, the resistance pattern among invasive clinical isolates collected prospectively and 
correlations between resistance and clinical parameters was investigated.  
 
4.1 PAPER I 
In paper I, an individual-based network model was constructed by employing 
demographic data from Sweden during the mid-2000s. An in silico population 
consisting of 25,000 individuals were set up and each individual was assigned age 
according existing data. Contact sites included were households, DCCs, school classes, 
and other contacts, which implicates close contacts occurring that may transmit 
pneumococci, for example interactions between children and their grandparents. The 
model considered asymptomatic carriers as the transmission reservoir for pneumococci 
in the community. Individuals colonized with pneumococci can transmit this microbe 
to susceptible individuals with whom they have an existing contact as defined by the 
contact network. Transmission occurs between individuals with certain probability 
depending on the contact type and age of the exposed individual. Duration of carriage 
appears to vary widely, however, an inverse relationship between age and carriage 
duration has been observed (Ekdahl et al. 1997). Each colonized individual was 
assigned a carriage duration at the time point for colonization, where the duration was 
drawn from an exponential distribution with a mean dependent on the age of the 
individual. The model was validated by comparing the age distribution for prevalence 
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of pneumococcal carriage obtained from computer simulations with observed data 
(Hogberg et al. 2007) (Figure 10).  
 
 
FIGURE 10  Age  distribution  among  pneumococcal  carriers.  The  carriage  prevalence  in  different  age  groups 
obtained from model simulations were compared with observed data (Hogberg et al. 2007).  
 
To elucidate which of the model parameters affects the transmission process mostly, a 
parameter analysis was performed. For each parameter tested, one hundred simulations 
were performed with varying values of the parameter of interest, while keeping all 
others parameter unchanged.  The parameter values were given by randomly assigning 
from a normal distribution with a mean equal to its default value and a standard 
deviation of 10% of the parameters default value. By calculating elasticity coefficients 
for individual parameters, we were able to assess their impact on pneumococcal 
transmission. Three parameters were revealed as key determinants: Carriage duration, 
Day-care transmission probability, and Group size in the DCCs. Duration of carriage 
has been reported to vary with pneumococcal serotype besides host factors. Although 
carriage duration is an important factor, it is difficult to affect and therefore cannot be 
considered as an interventional option. Also transmission probability in the DCCs 
appears to be highly relevant and may probably be lowered by improved hygiene 
routines. Further studies are required to identify more specific factors affecting the 
DCC transmission probability. The sizes of DCC groups seem to possess a very 
important role in pneumococcal transmission dynamic. Reduced DCC group sizes on 
community-level in the model, resulted in a distinct decline in pneumococcal 
transmission. This concurs with a study reporting that the pneumococcal carriage rate is 
much higher in DCC facilities attended by more than or equal to 45 children, than in 
centers with less than 45 children (Rosen et al. 1984). We also simulated three different 
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intervention scenarios: 1) Varying proportion of children attending day-care; 2) 
Different sizes of day-care groups; and 3) Restriction of day-care attendance for pre-
school children. The scenario simulations support the importance of the group size in 
DCCs. A decrease from 16.7 to 13.4 children at average for the DCC group size, the 
model predicts a reduction in transmission of 82%.  
 
4.2 PAPER II 
In paper II the spreading dynamic for pneumococci was further studied. The starting 
point was an individual-based network model similar that constructed in paper I. The 
in silico population was extended to comprise of 50,000 individuals, and the model 
considered spread of two competing pneumococcal clones; one clone was assumed to 
be fully susceptible whereas the other one was defined as PNSP. Outpatient penicillin 
users were initiated according available data of penicillin sales in Sweden during 2008 
for different age groups. If an individual who received penicillin at the same time was 
carrying pneumococci, different outcomes were possible dependent on the resistance 
characteristics of the colonizing clone. Carriages of susceptible strains were considered 
to be cleared in 80% of the cases, while PNSP carriages were assumed not to be 
eradicated by penicillin treatment. The model also considered the progression from 
carriage to clinical disease requiring outpatient penicillin treatment. The calculated 
risks for disease progression were only based on the age and did not considered any 
other risk factors. The risks for disease progression were estimated by determining the 
ratio between the age-specific incidence of pneumococcal disease and the incidence of 
pneumococcal carriage in defined age-groups. In Figure 11, the estimated disease risks 
for different age groups are presented.  
 
 
FIGURE 11  Age‐related risks for disease progression per individual colonization event. 
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Simulations of the model revealed that the age distribution for PNSP carriage 
prevalence is affected by penicillin consumption, whereas the age distribution of 
carriage prevalence appears not to be changed for the susceptible strain. The 
proportional prevalence increased for children between one to two years of age while it 
decreased for adults >18 years (Figure 12).  
 
 
FIGURE 12  Age distribution  for pneumococcal  carriage prevalence  for different model  scenarios.  Scenario  1.1 
reflects spread of a susceptible strain  in non‐penicillin consuming population; scenario 1.2 represents spread of a 
susceptible strain under the selection pressure of penicillin; and scenario 1.3 shows spread of a PNSP strain under 
the selection pressure of penicillin.  
 
The absolute incidence of PNSP, however, increased in all age groups under selective 
pressure of penicillin. Furthermore, simulations also showed that decreased penicillin 
usage in pre-school children (age 0-4 years) had an almost as extensive impact as 
reducing the overall penicillin consumption. This suggests that this age group should be 
the primary target for reducing unnecessary penicillin use in order to decrease the 
selection pressure on PNSP.  
According to the model, it appears very difficult to reduce the absolute 
frequency of PNSP simply by controlling the penicillin consumption assumed that 
penicillin resistance does not confer any fitness cost. For resistant organisms lacking 
such a biological cost, transmission control measures are very important. Examples of 
interventions aiming to reduce pneumococcal transmission include hygienic measures, 
vaccine programs, identification and isolation of individuals carrying PNSP, and 
reduced group size in DCCs (paper I). Introduction of national immunization programs 
will decrease the vaccine serotypes mainly associated with penicillin resistance; five of 
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the seven serotypes included in the 7-valent vaccine (6B, 9V, 14, 19F, and 23F) are 
those most often associated with penicillin resistance (Schrag et al. 2000). Combining 
large-scale use of vaccines with a more restrictive penicillin policy decreases the risk of 
selecting resistant non-vaccine types.  
 
4.3 PAPER III 
In paper III, a mathematical model of the regulation of competence was developed. 
The model consisted of non-linear ODEs describing the components involved in the 
competence-evoking pathway. Parameter values were assigned from published data as 
far as possible, however, experimental data could not be found for all. Instead, those 
parameters were estimated from biological plausibility. All parameters were tested in a 
wide range of values proving that the qualitative behavior of a system is determined 
chiefly by the network structure rather than specific parameter values. In the model, the 
quorum sensing regulated dynamic were investigated by increasing the extracellular 
concentration of CSP in the model which in turn affected the level of phosphorylated 
response regulator in the bacteria (Figure 13). 
 
 
FIGURE 13  Steady  state  amount  of  ComE~P  as  a  function  of  extracellular  concentration  of  CSP.  At  low  CSP 
concentration, ComE~P has a low steady state level and the com system is not activated. As CSP reached a certain 
threshold value (con), the steady state level of ComE~P jumps up to a higher value and will only go back to the lower 
steady state if CSP concentration decreases enough to pass another switch point (coff). 
 
At low CSP concentration, the steady state level of ComE~P is low. As CSP reaches a 
certain threshold concentration (con in Figure 13), the level of ComE~P increases and 
the com system becomes activated. The system is only turned off if the CSP 
concentration decreases to levels much lower than the concentration required for 
activating the system (coff in Figure 13). Changing the control parameter CSP may 
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switch the system state between the two stable branches. Such discontinuous toggle 
switches are called hysteresis, which may also be described as the lag between making 
a change and the response or the effect of that change.  
We sought to point out mechanisms responsible for the shut-down of 
competence, and therefore an elasticity analysis was performed to examine the impact 
of the individual parameters. The elasticity was investigated in the fold bifurcations (con 
and coff in Figure 13) of the hysteresis curve by computing the elasticity of each 
parameter. From this analysis, the off-switching fold appears to be most sensitive to 
changes occurring at the transcriptional level suggesting that the down-regulation of 
competence probably is mediated by a repressor acting on the comCDE operon. Next, 
the model was extended by introducing a repressor shutoff mechanism. Oscillating 
dynamics in the pneumococcal competence was then observed. Depending on the 
parameter values, the system was demonstrated to exhibit damped or sustained 
oscillations (Figure 14). This dynamic is in consistency with previous experimental 
studies which have reported waves of competence in a pneumococcal batch culture 
(Chen et al. 1987; Morrison 1997). 
 
 
 
 
FIGURE 14  Sustained (A) and damped (B) oscillations in the competence system. By introducing a repressor in the 
model, competence appeared in waves. The dashed lines indicate the total amount of repressor, while the solid line 
represents the total amount of ComE~P.  
 
4.4 PAPER IV 
During 1998-2001, a total of 839 pneumococcal isolates from blood and CSF were 
collected prospectively in the counties of Västra Götaland and Halland in south-west 
Sweden (Berg et al. 2006). Of the 839 collected strains, 827 could be revived for 
(A)  (B)
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susceptibility testing. In paper IV, MIC-values to penicillin G, erythromycin, 
clindamycin, tetracycline, moxifloxacine, and TMP-SMX were determined using E-
test®. Isolates were classified as sensitive (S), indeterminate (I) or resistant (R) for all 
agents according to the SRGA system of species related breakpoints (www.srga.org). 
We found that 90% of the strains could be classified as S to all agents, whereas 10% 
were I or R to at least one antimicrobial agent. Of these 83 strains, 62 were non-
susceptible to only one antibiotic and the remaining 21 strains were non-susceptible to 
more than one agent. 2.7% of the isolates had reduced susceptibility to penicillin; none 
of these was R. For the other agents, the resistance proportions were as following: 
clindamycin 0.7%; tetracycline 1.9%; moxifloxacine 0.1%; and TMP-SMX 4%. 
Reduced susceptibility to at least one agent was compared with age, gender, clinical 
manifestation, underlying diseases, year of isolation, geographic region, and outcome, 
but no correlations were found. The serotype distribution differed between susceptible 
and non-susceptible isolates (Table 1).  
 
TABLE 1  Reduced  susceptibility  to  any  of  the  antibiotics  tested  among  the  most  prevalent  serotypes  in  S. 
pneumoniae.  
   
Reduced susceptibility to any agent 
 
 
Serotype 
 
Total no. of strains 
 
No. 
 
(%) 
 
p-value 
1 118 7 6 ns 
7F 88 0 0 0.0001a 
9V 71 12 17 ns 
14 70 28 40 <0.0001b 
4 68 0 0 0.001a 
12F 48 3 6 ns 
6B 36 6 17 ns 
3 34 0 0 0.04a 
23F 34 4 12 ns 
8 30 0 0 ns 
9N 29 1 3 ns 
6A 28 2 7 ns 
19A 26 5 19 ns 
22F 24 1 4 ns 
19F 21 7 33 0.003b 
Other serotypes 102 7 7  
All serotypes 827 83 10  
a Significantly lower; b significantly higher when compared with all other serotypes.  
 
Significantly lower proportions of serotypes 7F, 4, and 3 were I or R to at least one 
agent when compared with all other serotypes. In contrast, significantly higher 
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proportions of serotypes 14 and 19F had reduced susceptibility to at least one agent in 
comparison with all serotypes.  
The vaccine coverage rates for the respective vaccines among strains with 
decreased susceptibility against at least one antimicrobial agent (Table 2) were also 
examined. Vaccine coverage rates are relative high for the strains with reduced 
susceptibility to any agent, between 73-96% depending on the vaccine. In contrast, the 
proportion of vaccine-types among the fully susceptible strains is only 39% for the 7-
valent vaccine. 
 
TABLE 2  Vaccine coverage rates for all strains and for the strains with reduced susceptibility, respectively.  
 
 
Vaccine 
 
All 827 strains 
Vaccine types /all strains (%) 
All 83 strains with reduced  
susceptibility to ≥1 agent 
Vaccine types/all non-susceptible strains (%) 
7-valent 350/827(42) 61/83 (73) 
10-valent 557/827 (67) 68/83 (82) 
23-valent 781/827 (94) 80/83 (96) 
ap<0.0001; bp=0.003. 
 
The results of this study are generally in agreement with previous studies of invasive 
isolates from Sweden (Ekdahl et al. 1998; Hedlund et al. 2003; Hedlund et al. 1995; 
Sandgren et al. 2004). Probably, the low sales of antimicrobials compared with other 
countries (Cars et al. 2001) have contributed to the relatively favorable resistance 
situation in Sweden.  
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5 CONCLUSIONS 
• One of the most efficient strategies to reduce pneumococcal carriage and spread 
in the community seems to be decreasing the group sizes in the DCCs, i.e., 
fewer numbers of children per class room.  
 
• The penicillin consumption in the community appears to affect the age 
distribution of carriage prevalence of PNSP whereas the age distribution among 
carriers of susceptible pneumococci seems unaffected.  
 
• It seems extremely difficult to reduce the absolute level of PNSP by simply 
controlling the penicillin usage if PNSP does not confer any fitness cost for 
resistance. A more restrictive consumption of penicillin together with other 
control measures, e.g., vaccine programs, is then required to manage the 
penicillin resistance in pneumococci.  
 
• Decreased penicillin usage in pre-school children (age 0-4 years) appears to 
have almost as extensive impact as reduced overall penicillin consumption. This 
suggests that this age group should be the primary target for reducing 
unnecessary penicillin use in order to decrease the selection pressure on PNSP.  
 
• The molecular understanding of competence regulation is important to be able 
to prevent horizontal spread of resistance genes. Down-regulation of 
competence is suggested to occur at transcriptional level, possibly by a 
repressor acting on the comCDE operon.  
 
• The impact of antibiotic resistance in invasive pneumococcal infections remains 
limited in south-west Sweden. No correlations were found between reduced 
antibiotic susceptibility and age, gender, clinical manifestation, underlying 
diseases, year of isolation, geographic area or mortality.  
 
• The serotype distribution differs between invasive pneumococci with reduced 
susceptibility and fully susceptible pneumococcal strains. Isolates having 
decreased susceptibility to any of the antimicrobial agents tested belonged more 
frequently to serotypes included in the 7-valent vaccine.  
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Pneumokocken är en bakterie som orsakar mycket lidande runt om i världen och anses 
vara ansvarig för 1-2 miljoner dödsfall varje år. Den ger upphov till allvarliga 
sjukdomar såsom lunginflammation, hjärnhinneinflammation och sepsis. Men 
pneumokocken kan även orsaka mindre farliga infektioner som öroninflammationer 
och bihåleinflammationer. Vanligen är det fullt friska personer, framför allt yngre barn, 
som bär på pneumokocker utan att uppvisa symtom. Bakterierna koloniserar då bakre 
näsvägg och svalg, men orsakar ingen skada på sin värd. Emellanåt övergår dock 
bärarstadiet till sjukdom – exakt varför detta sker vet man inte, men förmodligen spelar 
både värdfaktorer och den specifika pneumokockens egenskaper in. Dessa symtomfria 
bärare är dock viktiga ur smittspridningssynpunkt då de för pneumokockerna vidare till 
andra människor, som i sin tur också blir friska bärare eller utvecklar sjukdom.  
Traditionellt sett har infektioner med pneumokocker behandlats med olika typer 
av antibiotika, framför allt penicillin. Men under de senaste decennierna har det blivit 
allt mer vanligt med resistenta pneumokocker. Resistens innebär att bakterierna har 
förändrats så att antibiotika inte längre är verksam mot dem. Den främsta orsaken till 
uppkomst och spridning av resistenta pneumokocker är den omfattande användningen 
av antibiotika. I stora delar av världen är resistenta pneumokocker ett betydande 
problem. I Sverige, där vi varit lite mer försiktiga med antibiotikaanvändning, har vi en 
lägre förekomst av resistens bland pneumokockerna. Det förekommer även 
multiresistenta pneumokocker, dvs. pneumokocker som är resistenta mot penicillin och 
minst två andra antibiotika. Infektioner orsakade av resistenta pneumokocker försvårar 
och fördröjer effektiv behandling – många gånger är adekvat behandling insatt i tid 
livsavgörande för patienten. Ökad insikt och kunskap kring uppkomst och spridning av 
resistenta pneumokocker är därför viktigt för framtiden. Målet med denna avhandling 
var ökad kunskap kring uppkomst och spridning av resistenta pneumokocker genom att 
använda teoretiska såväl som empiriska metoder.  
I den första artikeln konstruerades en kontaktnätverksmodell baserad på 
verkliga demografiska data som reflekterar dagens samhällsstruktur för ett 
genomsnittligt Sverige. Genom att bygga upp en fiktiv population, där individerna 
tilldelas unika egenskaper som ålder och sociala relationer, kan sedan smittspridning 
simuleras i populationen. Modellens olika parametrar analyserades i syfte att se vilken 
åtgärd i samhället som är mest effektiv ur smittspridningssynpunkt. Det som framgick 
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framförallt var betydelsen av gruppernas storlek på förskolorna, dvs. antalet barn per 
avdelning. Genom att simulera en minskning av antalet barn per förskolegrupp från 
16.7 till 13.4 så minskade smittspridningen av pneumokocker i samhället med 82 %.  
Denna nätverksmodell utökades i den andra artikeln genom att omfatta en 
större population och inkludera även spridning av två pneumokockstammar som 
konkurrerar mot varandra. Den ena stammen var penicillinresistent medan den andra 
var fullt känslig. Antibiotikaförbrukning enligt försäljningsdata i Sverige inkluderades 
också. Målet var att studera hur penicillinanvändningen påverkar spridningsdynamiken 
hos pneumokockerna. Simuleringsresultaten visade att den relativa andelen resistenta 
pneumokocker minskar i samhället vid minskad penicillinanvändning, men inte den 
absoluta förekomsten vilket kan förklaras genom penicillinets inhiberande effekt på de 
känsliga stammarna. Vidare studerades även hur penicillin påverkar 
åldersdistributionen hos pneumokockbärarna. Penicillinanvändning verkar leda till 
ökad förekomst av resistenta stammar hos de yngre barnen, medan åldersdistributionen 
för bärarna av de fullt känsliga pneumokockerna inte påverkades.   
Den tredje artikeln i avhandlingen handlar om en egenskap hos 
pneumokocken som har bidragit till dess resistensuppkomst. Bakterierna är nämligen 
kompetenta för naturlig transformation vilket innebär att de kan plocka upp DNA som 
finns i deras omgivande miljö. DNA:t sätts sedan in i deras eget genom och uttrycks. På 
så sätt kan pneumokockerna plocka upp genetiska fragment som kodar exempelvis för 
resistens, från andra pneumokocker men även från andra närbesläktade bakterier. 
Systemet som reglerar kompetensutvecklingen kallas ComABCDE. I artikel III 
konstruerades en matematisk modell som beskriver detta kompetenssystem. Vi kunde 
visa att systemet uppvisar ett så kallat hysteresis-beteende. En analys av modellens 
parametrar utfördes för att undersöka var systemet är mest känslig för störningar, m. a. 
o. var det skulle kosta minst för bakterien stänga av systemet. Analysen pekade på en 
repressor som möjlig mekanism och en utökad modell med repressor konstruerades. 
Kompetensen framträdde då i vågor vilket tidigare hade setts i experiment.  
I den fjärde artikeln studeras resistensmönstret hos kliniska isolat insamlade 
från patienter med invasiva pneumokockinfektioner. Denna prospektiva studie omfattar 
827 bakterieisolat insamlade under åren 1998-2001 i en region Västra Götaland och 
Halland. Isolaten analyserades med avseende på kapseltyp samt resistensnivå för sex 
olika antibiotika. Majoriteten av isolaten, 90 %, var fullt känsliga mot alla inkluderade 
antibiotika, medan 10 % hade minskad känslighet för minst ett antibiotikum. En liten 
del av isolaten, 2.7 % visade nedsatt känslighet mot penicillin, men ingen av dessa blev 
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klassad som resistent. Vi fann ingen korrelation mellan nedsatt känslighet mot minst ett 
antibiotikum och ålder, klinisk manifestation, bakomliggande sjukdomar eller utgång. 
Däremot såg kapseltypsfördelningen lite annorlunda mellan de fullt känsliga och de 
som hade nedsatt känslighet. De serotyper som ingår i det 7-valenta 
pneumokockvaccinet motsvarade 42 % av alla infektioner, medan motsvarande 
täckningsgrad för infektioner orsakade av pneumokocker med minskad känslighet för 
antibiotika var 73 %.  
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